

CURRICULUM VITAE

Name: Mark J. Kupersmith, M.D.
Roosevelt Hospital
1000 10th Ave.
New York, N.Y. 10019
Telephone: 212-636-3200
Fax: 212-636-3195
Email:mkuper@chpnet.org

Training:

Northwestern University Six Year Honors Medical Program, Evanston, Illinois
BS Medicine 1973

Northwestern University School of Medicine, Chicago, Illinois
MD with Distinction 1974

New York University/Bellevue Hospital/Manhattan VA Hospital Medical Centers
Neurology 1974-1976, 1977-1978
Ophthalmology 1976-1977, 1978-1980

Professional Appointments:

Professor of Neurology and Ophthalmology
Icahn School of Medicine at Mount Sinai
2014

Professor of Neurology and Ophthalmology
Albert Einstein School of Medicine
July 2005 to 2014

Professor of Neurology and Ophthalmology,
NYU School of Medicine
September 1, 1989 to July 2005.

Clinical Professor of Neurology Ophthalmology
New York University School of Medicine
July 2005 to present.

Director of Neuro-ophthalmology, Institute of Neurology and Neurosurgery, Beth Israel Medical
Center and Roosevelt Hospital
May 1997 to present

Attending Physician, Neurology and Ophthalmology NYU Tisch Hospital
July 1980 to present.

Director of Neuro-ophthalmology New York Eye and Ear Infirmary
August 1982 to present.

Surgeon Director New York Eye and Ear Infirmary
2005 to present; Secretary of Medical Board 2006; Chairman of Medical Board 2007-2009

Director of Neuro-ophthalmology research for North American Neuro-ophthalmology
2001 to present

Ad hoc consultant to NIH National Institute of Neurological Disorder and Stroke
2002 to 2004

Consultant and Study Design for Boehringer and Ingelheim Mirepax FDA, mandated vision
safety prospective multicenter study.
2004 to 2009.

Editor for Americas: Neuro-ophthalmology 2002 to 2004

Director of Research for Neuro-ophthalmology – appointed Spring 2001 to 2008 by North
American Neuro-Ophthalmology Society

Prior Research Grants:

Corticosteroid treatment in the prevention of generalized disease in ocular myasthenia gravis. PI:
MJ Kupersmith, MD, co-PI H Kaminksi, MD. Multicenter phase III trial pilot data collection
\$100,000, Michael Fischer Fdn. 2002 to 2004

Prednisone Ocular Myasthenia Gravis Trial Planning Grant. PI: MJ Kupersmith, MD, co-PI: H
Kaminksi, MD. Multicenter phase III trial planning grant NINDS. Total Cost \$203,608 07/04 to
present; R34 NS046283-01A1

Optic Neuritis Model for Demyelination Neuroprotection. PI: MJ Kupersmith. Pearle Vision
Foundation \$14,000. 2007-2008

Ocular Coherence Tomography and Scanning Laser Polarimetry Evaluation of Retinal
Peripapillary Retinal Nerve Fiber Layer in Acute Optic Neuritis. PI: MJ Kupersmith. Teva
Pharmaceutical \$13,000. 2007-2008

Oral Megadose Corticosteroid Therapy of Acute Exacerbations in MS (OMEGA). F Lublin PI,
MJ Kupersmith co-PI, \$790,000, National MS Society, 2001-2008

Neuro-Ophthalmology Clinical Trials Workshop for 50 Neuro-Ophthalmologists in US and
Canada to be held at Roosevelt Hospital November 21 and 22. MK Kupersmith PI. NEI support
\$60,000

Octagon: A Randomized, Double Blind, Placebo Controlled, Multicenter Study of the Effects of Glatiramer Acetate (GA) on the Retinal Nerve Fiber Layer (RNFL) and Visual Function in Patients with a First Episode of Acute Optic Neuritis (AON); MJ Kupersmith co-PI, Teva Pharmaceutical. February 2009- February 2011. 40 site study

Scanning Laser Polarimetry (GDx) and High Definition Optical Coherence Tomography to detect changes in the peripapillary nerve fiber layer with optic nerve damage and morphometrics alterations in the optic nerve head 2010 Empire Clinical Research Investigator Program (ECRIP) awards for 2011-2012. \$150,000

Current Research Grants:

Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC). NEI: 1 U10 EY017281-01A1 (PI, Chair) Kupersmith MJ. Approximately \$ 9,835,688.00 from 2/06/09 – 1/31/15. Partner with University of Rochester 1 U10 EY017387-01A1 (Dr. Karl Kiebertz, PI)

Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Network. NEI under ARRA Recovery Act 2009. 3U10EY017281-01A1S1. \$799,913(PI, Chair) Kupersmith MJ. \$799,913. 9/01/09-8/31/11.

Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) OCT Substudy for IIHT. NEI: 3U10EY017281-04S1. PI Kupersmith MJ. \$483,603 .02/01/12-01/31/14 – extended to 1/31/15.

Ocular Myasthenia Gravis biomarker: miRNA, cytokine, and metaobolomic exploratory study. Kriser Fdn. PI Kupersmith MJ. \$125,000. 1/1/12- present.

Determining the earliest structure biomarker that predicts vision outcome and structure loss with acute optic nerve injury. Development of Center for Clinical Research to Prevent Neuronal Injury and Loss as Causes of Blindness at NY Eye and Ear Infirmary. Empire Clinical Research Investigator Program (ERIP). Mark J. Kupersmith, MD, Program Director; 2013-2014. \$598,833 per year for two years

Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC) Administrative supplement. NEI: U10EY017281-06S2. PI Kupersmith MJ. \$163,076. 09/01/14-01/31/15.

Pending submitted NIH grants (Review Fall 2014):

Longitudinal Idiopathic Intracranial Hypertension Trial (LIIHT) for NORDIC. PI Kupersmith MJ. U10. \$3,489,152. 04/01/2015 to 03/31/2019.

Hemianopia Intervention Study (HIS) for NORDIC. PI Feldon S. Enrollment Center and Resource Center PI Kupersmith, MJ. U10. \$3,399,137. 04/01/15-03/31/2018

Functional Magnetic Resonance Imaging of the Human Optic Nerve. PI Kupersmith M. U01. \$3,529,227. 04/01/2015 – 03/31/2019

Resident/fellow training

1980-1997 NYU Medical Center Ophthalmology and Neurology residents

1980- presently: New York Eye and Ear Infirmary residents

1986- yearly Neuro-Ophthalmology fellowship – suspended as of 2003 due to effort required to create and direct NORDIC

License: NYS 129274

Awards, invitations:

Visiting lecture, teaching rounds numerous Ophthalmology and Neurology departments through out the US including: UCLA, Columbia, Cornell, Michigan State, U Iowa, U Minnesota, Mayo Clinic, Wills, Washington Medical Center, U Florida, Temple, Yale, Ohio State, Nebraska Ophthalmology Society, Myasthenia Gravis Foundation

Invited moderator and lecturer in numerous countries including U Glasgow, Litchfield lecture at Oxford, British Isles Neuro-ophthalmology Society (BINOC), Queens Square, U Navarre Pamplona, European Neuro-Ophthalmology Society in Moscow, Guttenberg, Tubingen, Istanbul, Israel Ophthalmological Society, Telaviv University, Canadian Ophthalmology Society, Australian Neurological Society, Argentina Myasthenia Gravis Society, Venezuela Ophthalmology Society, U Geneva, Swiss Ophthalmology Society, Australian Neurological Society

Moderator, invited discussant, symposium participant at AAO, NANOS, ARVO, AAN including 2014

North American Neuro-Ophthalmology Society Distinguished Service Award 2009
Hoyt Lecture, AAO, October 19, 2014

Original Publications:

1975

1. Boshes B, Moody R, Kupersmith M, and Zeller A: The Role of Monoamines in Learning and Memory Consolidation. *International Journal of Neurology* 10:172-177, 1975.

1976

2. Gordon W, Holzman R, Senter H, Lara E, and Kupersmith M: *Aspergillus Oryzae* Meningitis. *JAMA* 235:2122-2123, 1976.

3. Lieberman A, Kupersmith M, Estey E, et al: Treatment of Parkinson's Disease with Bromocriptine. *New Engl J Med* 295:1400-1404, 1976.

1977

4. Lieberman A, Estey E, Kupersmith M, et al: Treatment of Parkinson's Disease with Lergotrile Mesylate. *JAMA* 238:2380-2382, 1977.

5. 1978

6. Lieberman A, Hass WK, Pinto R, Isom O, Kupersmith M, et al. Intracranial Hemorrhage and Infarction in Anticoagulated Patients with Prosthetic Heart Valves. *Stroke* 9:18-24, 1978.

1979

7. Lieberman A, Kupersmith M, Gopinathan G, Estey E, Goodgold A, and Goldstein M: Bromocriptine in Parkinson's Disease: Further Studies. *Neurology* 29:363-369, 1979.
8. Lieberman A, Kupersmith M, Gopinathan G, Estey E, Goodgold A, and Goldstein M: Lergotrile in Parkinson's Disease: Further Studies. *Neurology* 29:267-272, 1979.
9. Kupersmith M and Hass W: Visual Symptoms in Migraine and Their Treatment. *Stroke* 10:299-305, 1979.
10. Kupersmith M, Lieberman A, Spielholz N, Berczeller P, and Ransohoff J: Neuropathy with Susceptibility to Compression Aggravated by Herniated Disc: Early Pathological and Electro-diagnostic Studies. *Arch Neurology* 36:645-647, 1979.
11. Lieberman A, Kupersmith M, Neophytides A, Casson I, Durso R, Foo SH, Khayali M, Tantaro T: Bromocriptine Mesylate in Parkinson's Disease *New York State J Med* 79:1689-1692, 1979.
12. Lieberman A, Dziatolowski M, Kupersmith M, Serby M, Goodgold A, Korein J, and Goldstein M: Dementia in Parkinson Disease. *Ann Neurology* 6:355-359, 1979.
13. Lieberman A, Kupersmith M, Casson I, Durso R, Foo SH, Khayali M, and Tartaro T: Bromocriptine and Lergotrile: Comparative Efficacy in Parkinson Disease. *Adv in Neurology* 24:461-463, 1979.
14. Lieberman A, Dziatolowski M, Kupersmith M, Serby M, Korein J, and Goldstein M: Dementias of Huntington's and Parkinson Disease. *Adv Neurology* 23:273-280, 1979.

1980

15. Kleinberg D, Lieberman A, Todd J, Greising J, Neophytides A, Kupersmith M: Pergolide Mesylate: A Potent Day-Long Inhibitor of Prolactin in Rhesus Monkeys and Patients with Parkinson's Disease. *J of Clinical Endocrinol and Metab* 51:152-154, 1980.
 16. Kupersmith M, Goldstein M: The Effect of Decortication on the Basal Ganglia Gaba Receptor. *Neuroscience Letters* 17:335-337, 1980.
 17. Kupersmith M, Lieberman A, and Goldstein M: The Effect of Specific Brain Lesions on the High Affinity Binding of Gaba in the Substantia Nigra. *Brain Res* 194:536-539, 1980.
 18. Lieberman A, Kupersmith M, Neophytides A, Casson I, Durso R, Foo SH, Khayali M, Bear G, and Goldstein M: Long-term Efficacy of Bromocriptine in Parkinson's Disease. *Neurology* 30:518-523, 1980.
 19. Lieberman A, Dziatolowski M, Gopinathan G, Kupersmith M, Neophytides A, and Korein J: Evaluation of Parkinson's Disease.. *Adv in Biochemical Psychopharmacology* 23:277-286, 1980.
- 1981
20. Kupersmith M and Berenstein A: Visual Disturbances in Von Hippel Lindau's Disease. *Ann Ophthalmol* 13:195-197, 1981.
 21. Kupersmith M, Shakin E, Siegel I, Carr R, Ransohoff J, and Flamm E: Visual Evoked Potentials in Chiasmal Gliomas in Four Adults. *Arch Neurol* 38:362-365, 1981.
 22. Kupersmith M, Siegel I, and Carr R: Reduced Contrast Sensitivity in Compressive Lesions of the Anterior Visual Pathway. *Neurology* 31:550-554, 1981.
 23. Korein J, Lieberman A, Kupersmith M, and Levidown L: Effect of L-Glutamine and Isoniazid on Torticollis and Segmental Dystonia. *Ann Neurol* 10:247-250, 1981.
 24. Lieberman A, Goldstein M, Leibowitz M, Neophytides A, Kupersmith M, Peck V, Kleinberg D: Treatment of Advanced Parkinson's Disease with Pergolide. *Neurology* 31:675-682, 1981.
 25. Lieberman A, Goldstein M, Neophytides A, Kupersmith M, Leibowitz M, Zasorin N, Walker R, and Kleinberg D: Lisuride in Parkinson's Disease: Efficacy of Lisuride Compared to Levadopa. *Neurology* 31:961-965, 1981.
 26. Leibowitz M, Lieberman A, Goldstein M, Neophytides A, Kupersmith M, and Mehl S: The Cardiac Effects of Pergolide: A Potent and Long-Acting Dopamine Agonist. *Clin Pharmacol and Therap* 30:718-723, 1981.

1982

27. Kupersmith M, Siegel I, Shakin E, Lieberman A: Visual System Dysfunction in Parkinson's Disease. *Arch Neurol* 39:284-286, 1982.
 28. Kupersmith M, Siegel I, Carr R: Subtle Disturbances of Vision With Compressive Lesions of the Anterior Visual Pathway Measured by Contrast Sensitivity. *Ophthalmology* 82:68-72, 1982.
- 1983
29. Kupersmith M, Nelson J, Seiple W, Weiss P, Carr R: The 20/20 Eye in Multiple Sclerosis. *Neurology* 33:1015-1020, 1983.
 30. Seiple WH, Price MJ, Kupersmith MJ, Siegel IM, and Carr RE: The Pattern Electroretinogram in Optic Nerve Disease. *Ophthalmology* 90:1127-1132, 1983.
 31. Kupersmith MJ, Weiss PA, and Carr RE: The Visual Evoked Potential in Tobacco-Alcohol and Nutritional Amblyopias. *Am J Ophthalmol* 95:307-314, 1983.
- 1984
32. Kupersmith MJ, Berenstein A, Flamm E, and Ransohoff J: Percutaneous Transvascular Treatment of Giant Carotid Aneurysms: Neuro-ophthalmologic Findings. *Neurology* 34:328-335, 1984.
 33. Berenstein A, Ransohoff J, Kupersmith M, Flamm E, and Graeb D: Transvascular Treatment of Giant Aneurysms of the Cavernous Carotid and Vertebral Arteries. Functional Investigation and Embolization. *Surg Neurol* 21:3-12, 1984.
 34. Kupersmith MJ, Aleksic SN: Bilateral Pupillary Cholinergic Supersensitivity in a Case of Sarcoidosis. *Neuro-ophthalmology* 4:215-230, 1984.
 35. Kupersmith M, Krohn D: Cupping of the Optic Disc with Compressive Lesions of the Anterior Visual Pathway. *Ann Ophthalmology* 16:948-953, 1984.
 36. Nelson JI, Kupersmith MJ, Seiple WH, Weiss P, and Carr RE: Spatiotemporal Conditions Which Elicit or Abolish the Oblique Effect in Man: Direct Measurement with Swept Evoked Potential. *Vis Res* 24:579-586, 1984.
 37. Nelson JI, Kupersmith MJ, Seiple WH, Carr RE: The Swept Display Technique: Separation of the X- and Y- Dominated Evoked Potentials. *Evoked Potentials II, The Second International Evoked Potentials Symposium*, Butterworth Publishers, ed. Nodar, R. and Barber, C., pp.123-134, 1984.
 38. Seiple WH, Kupersmith MJ, Nelson JI, and Carr RE: The Assessment of Evoked Potential Contrast Thresholds Using Real-Time Retrieval. *Invest Ophthalm* 25:627-631,

1984.

39. Nelson JI, Seiple WH, Kupersmith MJ, Carr RE: Lock-in Techniques for the Swept Stimulus Evoked Potential. *J Clin Neurophys* 1(4):409-436, 1984.
40. Kupersmith MJ, Seiple WH, Nelson JI, Carr RE: Contrast Sensitivity Loss in Multiple Sclerosis: Selectivity by Eye, Orientation, and Spatial Frequency Confirmed with Evoked Potential Assessment. *Invest Ophthalmol Vis Sci* 25:632-639, 1984.
41. Nelson JI, Seiple WH, Kupersmith MJ, Carr RE: A Rapid Evoked Potential Index of Cortical Adaptation. *Electro-encephalography and Clinical Neurophysiology* 59:454-464, 1984.
42. Noble KG and Kupersmith MJ: "Retinal Vascular Remodelling in Radiation Retinopathy". *Br J of Ophthal* 68:475-478, 1984.

1985

43. Weiner DE, Wellish K, Nelson JI, Kupersmith MJ: Comparisons Among Snellen, Psychophysical and Evoked Potential Visual Acuity Determinations. *Am J of Optometry and Physiology Optics* 62:669-679, 1985.
44. Kupersmith MJ, Nelson JI, Seiple WH, Carr RE: Electro-physiological Confirmation of Orientation-Specific Contrast Losses in Multiple Sclerosis. *Ann New York Acad Sci* 436:487-491, 1985.
45. Frohman LP, Kupersmith MJ: Reversible Vertical Ocular Deviations Associated With Raised Intracranial Pressure. *J of Clin Neuro-Ophthalmol* 5:158-163, 1985.
46. Frohman LP, Epstein F, Kupersmith MJ: Atypical Visual Prognosis with an Optic Nerve Glioma. *J Clin Neuro-Ophthalmol* 5:90-94, 1985.
47. Cohen AR, Cooper PR, Kupersmith MJ, Flamm ES, Ransohoff J: Visual Recovery After Transphenoidal Removal of Pituitary Adenomas. *Neurosurgery* 17:446-452, 1985.

1986

48. Frohman LP, Kupersmith MJ, Lang J, Reede D, Bergeron RT, Aleksic S, and Trasi S: Intracranial Extension and Bone Destruction in Orbital Pseudotumor. *Arch Ophthalmol* 104:380-384, 1986.
49. Kupersmith MJ, Berenstein A, Flamm E, and Ransohoff, J. Neuro-Ophthalmologic Abnormalities and Intravascular Therapy of Carotid Cavernous Fistulas. *Ophthalmology* 93:906-912, 1986.

50. Weinreb H, Klein J, and Kupersmith MJ. Ocular Myasthenia Gravis and Chronic Inflammatory Polyradiculoneuropathy. *New York State J Med*, 439-442, 1986.
 51. Foo SH, Choi IS, Berenstein A, Wise A, Ransohoff J, Koslow M, George A, Lin J, Feigin I, Budzilovich G, Kupersmith M, Hanson R, Lequerica S, Aleksic S, and Kricheff I: Supraophthalmic Intracarotid Infusion of BCNU for Malignant Glioma. *Neurology* 36:1437-1444, 1986.
 52. Kupersmith MJ, Nelson JI: Preserved Visual Evoked Potential in Infancy Cortical Blindness: Relationship to Blindsight. *Neuro-ophthalmology* 6:85-94, 1986.
- 1987
53. Frohman LP, Pinto RP, Warren FA, and Kupersmith MJ: Metrizamide Computed Tomographic Cisternography: Procedure of Choice for Chiasmal Syndromes with Equivocal Computed Tomographic Scans. *Neuro-ophthalmology* 7:251-265, 1987.
 54. Kupersmith MJ, Warren FA, Hass WK: The Non-Benign Aspects of Migraine. *Neuro-ophthalmology* 7:1-10, 1987.
 55. Kupersmith MJ, Warren FA, Newall J, and Ransohoff J: Irradiation of Meningiomas of the Intracranial Anterior Visual Pathway. *Ann Neurol* 21:131-136, 1987.
 56. Wilson GB, Lloyd LA, Buncic JR, Younge BR, Grimson BS, Shults WT, Lubow M, Slamovits TL, Wirtschafter JD, Kupersmith MJ, and Lessell S: Tumor Spread in Unilateral Optic Glioma - I. *Neuro-ophthalmology* 7:179-184, 1987.
- 1988
57. Gelwan M, Pile-Spellman J, Berenstein A, Choi I, Kupersmith M: Dural Arteriovenous Malformations and Papilledema. *Neurosurgery* 22:1079-1084, 1988.
 58. Kupersmith MJ, Frohman LP, Choi IS, Foo SH, Hiesinger E, Berenstein A, Wise A, Carr RE, and Ransohoff J: Visual System Toxicity Following Intra-Arterial Chemotherapy. *Neurology* 38:284-289, 1988.
 59. Gelwan M, Kupersmith MJ, Burde R: Sarcoid Optic Neuropathy - Treatment Considerations. *J Neurol, Neurosurg Psychiatr* 51:1473-1480, 1988.
 60. Gelwan M, Kupersmith MJ: Pseudo-Pseudo-Foster Kennedy Syndrome. *J Clin Neuro-ophthalmology* 8:49-52, 1988.
 61. Kupersmith MJ, Berenstein A, Choi IS, Warren F, Flamm E: Management of Spontaneous Vascular Shunts Involving the Cavernous Sinus. *Ophthalmology* 95:121-130, 1988.

62. Kupersmith MJ, Burde RM, Warren FA, Klingele TG, Frohman LP, and Mitnick H: Autoimmune Optic Neuropathy - Evaluation and Treatment. *J Neurol, Neurosurg, Psychiatr* 51:1381-1386, 1988.
63. Seiple WH, Kupersmith MJ, Nelson JJ, Carr RE: Evoked Potential Assessment of Cortical Adaptation. *Applied Optics* 27:1089-1093, 1988.
64. Kupersmith MJ, H, Frohman L, et al: Ocular Myasthenia: Diagnosis and Treatment. *Neuro-ophthalmology Enters the Nineties*, J. Lawton-Smith, R Katz (eds), Dutton Press; 178-182, 1988.
65. Beck RW, Optic Neuritis Study Group: The Optic Neuritis Treatment Trial. *Arch Ophthalmol* 106:1051-1053, 1988.
- 1989
66. Kupersmith MJ, Kleinberg D, Warren FA, Budzilovitch G, Cooper P: Growth Prolactinoma Despite Lowering of Serum Prolactin by Bromocriptine. *Neurosurgery* 24:417-423, 1989.
- 1990
67. Rush SC, Kupersmith MJ, Lerch I, Cooper P, Ransohoff J, and Newall J: Neuro-ophthalmological assessment of vision before and after radiation therapy alone for pituitary macroadenomas. *J Neurosurg* 72:594-599, 1990.
- 1991
68. Noble K, Kupersmith MJ: Spontaneous Retinal Capillary Reperfusion in a Systemic Illness. *Archives of Ophthalmology* 109:179180, 1991.
69. Capo H, Kupersmith MJ: Efficacy and Complications of Radiotherapy of Anterior Visual Pathway Tumors. *Neurologic Clinics* 9:179-203, 1991.
70. Holopigian K, Seiple W, Kupersmith M: VEP Threshold and Suprathreshold Deficits in Amblyopia. *Clin Vis Sci* 6:109-117,1991.
71. Capo H, Kupersmith MJ, Berenstein A, Choi IS, Diamond GA: The Clinical Importance of the Inferolateral Trunk of the Internal Carotid Artery. *Neurosurgery* 28:733-738,1991.
72. Optic Neuritis Study Group: The Clinical Profile of Optic Neuritis. Experience of the Optic Neuritis Treatment Trial. *Arch Ophthalmol* 109:1673-1678, 1991.
- 1992
73. Beck RW, Cleary PA, Anderson MM, Kupersmith MJ, et al: A Randomized, Controlled

- Trial of Corticosteroids in the Treatment of Acute Optic Neuritis. *N Engl J Med* 326:581-588, 1992.
74. Capo H, Warren F, Kupersmith MJ: Evolution of Oculomotor Nerve Palsies. *J Clin Neuro-Ophthalmol* 12:21-25, 1992.
 75. Kupersmith MJ, Seiple WH, Holopigian K, Noble K, Hiesiger E, & Warren F: Maculopathy Caused by Intra-Arterial Administered Cisplatin and Intravenously Administered Carmustine. *Am J Ophthalmol* 113:435-438, 1992.
 76. Capo H, Warren F, Kupersmith MJ. Evaluation of a third cranial nerve palsy: an unresolved issue. *J Clin Neuro-ophthalmol* 12:21-25, 1992.
 77. Kupersmith MJ, Hurst R, Berenstein A, Choi IS, Jafar J, & Ransohoff J: The Benign Course of Cavernous Carotid Aneurysms. *J Neurosurg* 77:690-693, 1992.
 78. Kupersmith MJ, Gupta K, Seiple WH, Holopigian K. Optic atrophy fails to alter the flash electroretinogram. *Clin Vision Sci* 7:247-250, 1992.
 79. Beck, Optic Neuritis Study Group: The Optic Neuritis Treatment. Implications for Clinical Practice. *Archives of Ophthalmology* 110:331-332, 1992
 80. Beck RW, Optic Neuritis Study Group: Corticosteroid Treatment of Optic Neuritis. A Need to Change Treatment Practices. *Neurology* 42:1133-1135, 1992.
 81. Vargas ME, Desrouleaux JR, Kupersmith MJ: Ophthalmoplegia as a Presenting Manifestation of Internal Carotid Artery Dissection. *J Clin Neuro-ophthalmol* 12:268-271, 1992.
 82. Bielory L, Kupersmith M, Warren F, Bystryn J and Frohman L: Skin Biopsies in the Evaluation of Atypical Optic Neuropathies. *Ocular Immunol Inflammation* 1:231-241, 1992.
- 1993
83. Jafar JJ, Davis AJ, Berenstein A, Choi IS, Kupersmith MJ: The Effect of Embolization with N-butyl Cyanoacrylate Prior to Surgical Resection of Cerebral Arteriovenous Malformations. *J Neurosurg* 78:60-69, 1993.
 84. Beck RW, Kupersmith MJ, Cleary PA, Katz BJ, & ONTT Group: Fellow Eye Abnormalities in Acute Unilateral Optic Neuritis: Experience of the Optic Neuritis Treatment Trial. *Ophthalmology* 100:691-698, 1993.
 85. Vargas M, Warren F, Kupersmith MJ: Exotropia as a sign of myasthenia gravis in dysthyroid ophthalmopathy. *Br J Ophthalmol* 77:822-823, 1993.

86. Winterkorn J, Kupersmith MJ, Wirtschafter J, Forman S. Treatment of vasospastic amaurosis fugax with calcium channel blockers. *New Engl J Med* 329:396-398, 1993.
 87. Cleary PA, Beck RW, Anderson MM, Kenny DJ, Backlund J, Gilbert PR, and the Optic Neuritis Study Group. Design, Methods, and Conduct of the Optic Neuritis Treatment Trial. *Controlled Clinical Trials* 14:123-142, 1993
 88. Keltner JL, Johnson CA, Beck RW, Cleary PA, Spurr JO, and the Optic Neuritis Study Group. Quality Control Functions of the Visual Field Reading Center (VFRC) for the Optic Neuritis Treatment Trial (ONTT). *Controlled Clinical Trials* 14:143-159, 1993.
 89. Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI, and the Optic Neuritis Study Group: Brain Magnetic Resonance Imaging in Acute Optic Neuritis. Experience of the Optic Neuritis Study Group. *Arch Neurol* 50:841-846, 1993.
 90. Beck RW, Cleary PA, and the Optic Neuritis Study Group: Optic Neuritis Treatment Trial: One Year Follow up Results. *Arch Ophthalmol* 111:773-775, 1993.
 91. Beck RW, Cleary PA, Trobe JD, Kaufman DI, Kupersmith MJ, Paty DW, Brown CH, and the Optic Neuritis Study Group: The Effect of Corticosteroids on the Development of New Clinical Manifestations of Multiple Sclerosis in Patients with Acute, Isolated Optic Neuritis. "Corticosteroids Reduce MS Attack Rate". *N Engl J Med* 329:1764-1769, 1993.
 92. Keltner JL, Johnson CA, Spurr JO, Beck RW, Optic Neuritis Study Group: Baseline Visual Field Profile of Optic Neuritis: The Experience of the Optic Neuritis Treatment Trial. *Arch Ophthalmol* 111:231-234, 1993.
 93. Beck RW, Arrington J, Murtagh FR, Cleary PA, Kaufman DI, Optic Neuritis Study Group: Brain MRI in Acute Optic Neuritis: Experience of the Optic Neuritis Study Group. *Arch Neurol* 8:841-846, 1993.
 94. Beck RW, Cleary PA, Optic Neuritis Study Group: Recovery from Severe Visual Loss in Optic Neuritis. *Arch Ophthalmol* 111:300, 1993.
 95. Beck RW, Diehl L, Cleary PA, Optic Neuritis Study Group: The Pelli-Robson Letter Chart: Normative Data for Young Adults. *Clin Vis Sci* 8:207-210, 1993.
 96. Chrousos GA, Kattah JC, Beck RW, Cleary PA, Optic Neuritis Study Group: Side Effects of Glucocorticoid Treatment: Experience of the Optic Neuritis Treatment Trial. *JAMA* 269:2110-2112, 1993.
- 1994
97. Kupersmith MJ, Kaufman D, Paty W, Ebers G, McFarland H, Johnson K, Reingold S and Whitaker J. Megadose Corticosteroids in Multiple Sclerosis. *Neurology* 44:1-4, 1994.

98. Kupersmith MJ, Vargas M, Hoyt WF, Berenstein A. Optic tract atrophy with cerebral arteriovenous malformations: direct and transsynaptic degeneration. *Neurology* 44:80-83, 1994.
 99. Xin D, Kupersmith MJ, Holopigian K, Seiple W: Visual Evoked Potentials Following Abrupt Contrast Changes, *Vis Res* 34:2813-2821, 1994.
 100. Holopigian K, Clewner L, Seiple W, Kupersmith MJ: The Effects of Dopamine Blockade on the Human Flash Electroretinogram. *Doc Ophthalmol* 86:1-10, 1994.
 101. Vargas ME, Kupersmith MJ, Setton A, Nelson K, Berenstein A: Endovascular Treatment of Giant Aneurysms Which Cause Visual Loss. *Ophthalmology* 101:1091-1098, 1994.
 102. Kupersmith MJ, Rosenberg C, Kleinberg D: Visual Loss in Pregnant Women with Pituitary Adenomas. *Ann Intern Med* 121:473-477, 1994.
 103. Beck RW, Cleary PA, Jye-yu C, Backlund MS and The Optic Neuritis Study Group: The Course of Visual Recovery after Optic Neuritis. Experience of the Optic Neuritis Treatment Trial. *Ophthalmol* 101:1771-1778, 1994.
 104. Weiner HL, Rosenberg ME, Kupersmith MJ, Cohen H, Zagzag D, Shiminski-Maher T, Flamm ES, Epstein FJ, Miller DC: Craniopharyngiomas: A Clinicopathological Analysis of Factors Predictive of Recurrence and Functional Outcome. *Neurology* 35:1001-1011, 1994.
 105. Keltner JL, Johnson CA, Spurr JO, Beck RW, Optic Neuritis Study Group: Visual Field Profile of Optic Neuritis: One-year Follow up in the Optic Neuritis Treatment Trial. *Arch Ophthalmol* 112:946-953, 1994.
- 1995
106. Hurst RW, Berenstein A, Kupersmith MJ, Madrid M, Flamm ES: Deep Central Arteriovenous Malformations of the Brain: The Role of Endovascular Treatment. *J Neurosurg* 82:190-195, 1995.
 107. Vargas EM, Kupersmith MJ, Savino PJ, Petito F, Frohman LP, Warren FA: Homonymous Field Defect Manifestation of Creutzfeldt-Jakob Disease. *AJO* 119:497-504, 1995.
 108. Bose S, Kupersmith MJ: Neuro-Ophthalmological Presentations of Functional Visual Loss. *Neurology Clinics* 13:321-339, 1995.
 109. Beck RW, Trobe JD, Optic Neuritis Study Group: What We Have Learned from the Optic Neuritis Treatment Trial. *Ophthalmology* 102:1504-1508, 1995.

110. Beck RW, Trobe JD, and the Optic Neuritis Study Group: The Optic Neuritis Treatment Trial. Putting the Results in Perspective. *J Neuro-Ophthalmol* 15:131-135, 1995.
111. Beck RW, Optic Neuritis Study Group: The Optic Neuritis Treatment Trial. Three-year Follow Up Results. *Arch Ophthalmol* 113:136-137, 1995.
112. Anderson MM, Boly LD, Beck RW, Optic Neuritis Study Group: Remote Monitoring for Multicenter Trials. *Controlled Clinical Trials* 1996;17:407-414
- 1996
113. Rolak LA, Beck RW, Paty DW, Tourtellotte WW, Whitaker JN, Rudick RA, Optic Neuritis Study Group: Cerebrospinal fluid in acute optic neuritis: experience of the Optic Neuritis Treatment Trial. *Neurology* 46:368-372, 1996.
114. Kupersmith MJ, Vargas ME, Yashar A, Madrid M, Nelson K, Setton A, Berenstein A: Occipital arteriovenous malformations: Visual disturbances and presentation. *Neurology* 46:953-957, 1996.
115. Kupersmith MJ, Vargas EM, Warren F, Berenstein A: Venous Obstruction as the Cause of Retinal/Choroidal Dysfunction Associated with Arteriovenous Shunts in the Cavernous Sinus. *J Neuro-Ophthalmol* 16:1-6, 1996.
116. Kupersmith MJ, Warren F, Weinberg H, Moster M. Beneficial Effect Corticosteroids in Ocular Myasthenia Gravis. *Arch Neurol* 53:802-804,1996.
117. Nimi Y, Berenstein A, Setton A, Kupersmith M J. Occlusion of the Internal Carotid Artery Based on a Simple Tolerance Test. *Intervent Neuroradiol* 1996; 2:289-296.
118. Trobe J, Beck R, Moke P, Cleary P. Contrast sensitivity and other vision tests in the optic neuritis treatment trial. *Am J Ophthalmol* 1996;121:547-553.
- 1997
119. Optic Neuritis Study Group. Visual function five years after optic neuritis: experience of the optic neuritis treatment trial. *Arch Ophthalmol* 1997;115:1545-1552
120. Optic Neuritis Study Group. The 5-year risk of MS after optic neuritis: experience of the optic neuritis treatment trial. *Neurology* 1997; 49:1404-1413
121. Kupersmith MJ, Frohman L, Sanderson M, Jacobs J, Hirschfeld J, Ku C, Warren FA. Aspirin reduces the incidence of second eye NAION: a retrospective study. *J Neuro-ophthalmol* 1997; 17:250-253
122. Arginteanu MS, Hague K, Zimmerman R, Kupersmith MJ, Shaiu JH, Schaeffer J, Post KD. Craniopharyngioma arising de novo in middle age. Case report. *J Neurosurg*

1997:1046-1048

123. Cleary PA, Beck RW, Bourque L, Backlund P, Miskala P, Optic Neuritis Study Group. Visual symptoms after optic neuritis. Results from the Optic Neuritis Treatment Trial. *J Neuro-Ophthalmology* 1997;17:18-28

1998

124. Kupersmith MJ, Gamell L, Turbin R, Peck V, Spiegel P, Wall M. Effects of weight loss on the course of idiopathic intracranial hypertension in women. *Neurology* 1998;50:1094-1098

1999

125. Kupersmith MJ, Berenstein A, Nelson P, ApSimon HT, Setton A. Visual symptoms with dural arteriovenous malformations into occipital veins. *Neurology*, 1999;52:156-162
126. Kupersmith MJ, Langer R, Mitnick H, Speira R, Speira H, Richmond M, Paget S. Visual performance in giant cell arteritis (temporal arteritis) after one year of therapy. *Br J Ophthalmol* 1999;83:796-801
127. Barr D, Kupersmith MJ, Turbin R, Yang S, J, Iezzi R. Synkinesis following diabetic third nerve palsy. *Arch Ophthalmol* 2000;118:132-133
128. Barr D, Kupersmith MJ, Pinto R, Turbin R. Arachnoid cyst of the cavernous sinus resulting in third nerve palsy. *J Neuro-ophthalmol* 1999;19:249-251
129. Baron-Huna R, Lesser R, Warren F, Kupersmith MJ. Infantile aneurysms with visual pathway compression. *Pediatr Neurosurg* 1999;31:322-325
130. Keltner JL, Johnson CA, Spurr JO, Beck RW, Optic Neuritis Study Group. Comparison of central and peripheral visual field properties in the optic neuritis treatment trial. *Am J Ophthalmol* 1999;128:543-553

2000

131. Barr, D, Kupersmith MJ, Roth R, Turbin R, Bose S. Isolated sixth nerve palsy an uncommon presenting sign of multiple sclerosis: a retrospective study. *J Neurology* 2000; 247:701-704
132. Andracchi S, Kupersmith MJ, Nelson P, Slatker J, Setton A, Berenstein A. Visual loss from arterial steal in patients with maxillofacial arteriovenous malformation. *Ophthalmology* 2000;107:730-736
133. Huna-Baron R, Warren F, Miller W, Jacobs J, Green J, Kupersmith MJ. Mucosal leishmaniasis presenting as sinusitis and optic neuropathy. *Arch Ophthalmol*

2000;118:852-854

134. Cole S, Beck R, Moke P, Gal R, Long D, and the Optic Neuritis Study Group. The National Eye Institute Visual Function Questionnaire: experience of the ONTT. *Invest Ophthalmol Vis Sci* 2000;41:1017-1021
135. Huna-Baron R, Kupersmith MJ. Cerebral polyopia, neuroimaging localization. *Neuro-ophthalmology* 2000;267-271
136. Huna-Baron R, Setton A, Kupersmith, MJ. Orbital dural arteriovenous malformation. *Br J Ophthalmol* 2000; 84:771-774
137. Hauser SL, Oksenberg JR, Lincoln R, Garovoy, Beck RW, Cole SR, Moke PS, Kip KE, Gal RL, Long DT, and the Optic Neuritis Study Group. Interaction between HLA-DR2 and abnormal brain MRI in optic neuritis and MS. *Neurology* 2000;54:1859-1861
138. Jacobs LD, Beck RW, Simon JH, et al., and The CHAMPS Study Group. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. *New Engl J Med* 2000;343:898-904

2001

139. Kupersmith MJ, Kalish H, Epstein F, Yu G, Berenstein A, Woo H, Jafar J, Mandel G, De Lara F. Natural history of brainstem cavernous malformations. *Neurosurgery* 2001;48:47-54
140. Long D, Beck R, Moke P, Blair R, Kip K, Gal R, Katz B, the ONTT Study Group. The SKILL card test in optic neuritis: experience of the optic neuritis treatment trial. *J Neuro-ophthalmol* 2001;21:124-131
141. Huna-Baron R, Landau K, Rosenberg M, Warren F, Kupersmith MJ. Unilateral swollen disc due to increased intracranial pressure. *Neurology* 2001;56:1588-1590
142. Spiera RF, Mitnick HJ, Kupersmith MJ, Richmond M, Spiera H, Peterson MGE, Paget SA. A prospective double-blind randomized placebo-controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). *Clinical and Experimental Rheumatology* 2001;19:495-501
143. Kupersmith MJ, Speira R, Langer RL, Richmond M, Peterson M, Speira H, Mitnick H, Paget S. Visual function and quality of life among patients with giant cell (temporal) arteritis. *J Neuro-ophthalmology* 2001; 21:266-273
144. CHAMPS Study Group. Interferon B-1a for optic neuritis patients at high risk for multiple sclerosis. *Am J Ophthalmol* 2001;132:464-471

2002

145. Turbin RE, Thompson CS, Kennerdell JS, Cockerman KP, Kupersmith MJ. A long term visual outcome comparison in patients with optic nerve sheath meningioma managed with observation, surgery, radiotherapy, or combination surgery and radiotherapy. *Ophthalmology* 2002; 109:890-900
 146. Kupersmith MJ, Alban T, Zeiffer, B, Lefton D. Contrast enhanced MRI in acute optic neuritis: relationship to visual performance. *Brain* 2002; 125:812-822
 147. Stiebel-Kalish H, Setton A, Berenstein A, Kupersmith MJ. Bilateral orbital congestion is a risk factor for cortical venous drainage in cavernous sinus area dural arteriovenous malformations. *Neurology* 2002;58:1521-1524
 148. Kupersmith MJ, Stiebel-Kalish H, Huna-Baron R, Setton A, Niim Y, Langer D, Berenstein A. Cavernous carotid aneurysms rarely cause subarachnoid hemorrhage or major neurological morbidity. *J Stroke Cerebrovasc Dis* 2002; 11:9-14
 149. Beck R, Chandler D, Cole S, Simon J, Jacobs L, Kinkel P, Selhorst J, Rose J, Cooper J, Rice G, Murray T, Sandrock, for the CHAMPS Study Group. Interferon B-1a for early multiple sclerosis: CHAMPS trial subgroup analysis. *Ann Neurol* 2002;51:481-490
 150. CHAMPS Study Group. Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial. *Multiple Sclerosis* 2002;8:330-338
 151. Huna-Baron R, Kupersmith MJ. Idiopathic intracranial hypertension in pregnancy. *J Neurol* 2002; 749:1078-1081
 152. Steibel-Kalish H, Setton A, Niimii Y, Hartman J, Huna-Baron R, Berenstein A, Kupersmith MJ. Cavernous sinus dural arteriovenous malformations: Patterns of venous drainage are related to clinical signs and symptoms. *Ophthalmolgy* 2002;109:1685-1691
 153. CHAMPS Study Group. Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo group. *Multiple Sclerosis*. 2002;8:405-0409
 154. CHAMPS Study Group. MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group. *Neurology* 2002;59:998-1005
- 2003
155. Fazzone H, Lefton D, Kupersmith MJ. Acute occipital demyelinating lesions appearing as an infarct on diffusion magnetic resonance. *Am J Ophthalmol* 2003;96-97
 156. Kupersmith MJ, Latkany R. Development of generalized disease at two years in patients with ocular myasthenia gravis. *Arch Neurol* 2003;60:243-248

157. Fazzone H, Lefton D, Kupersmith MJ. Pain of optic neuritis. *Ophthalmology* 2003;110:1646-1649
158. Niimi Y, Kupersmith, MJ, Kalish H, Milea D, Setton A, Nelson PK, Pryor J, Berenstein A. Unusual presentation of carotid cavernous aneurysms. *Neuro-ophthalmology* 2001; 26: 169-179
159. Fazzone H, Kupersmith MJ, Liebmann J. Brimonidine treatment of non-arteritic anterior ischemic optic neuropathy. *Br J Ophthalmol* 2003;87:1193-1194
160. Optic Neuritis Study Group. High and low risk profiles for the development of multiple sclerosis within ten years after optic neuritis. Experience of the optic neuritis treatment trial. *Arch Ophthalmol* 2003; 121:944-949
- 2004
161. The Optic Neuritis Study Group. Visual function more than 10 years after optic neuritis: Experience of the optic neuritis treatment trial. *Am J Ophthal* 2004;137:77-83
162. Kupersmith MJ, Fazzone H. Ocular motor testing for clinical trials. *Arch Ophthalmol* 2004;122:347-348
163. Hickman S, Kupersmith MJ, Straga J, Egan R, Kraker R Lefton D, Miszkiel K, Miller D, Plant G. Upper temporal visual field depressions in the fellow eye in posterior acute optic neuritis: Involvement of Wilbrand's knee? *Neuro-ophthalmology* 2004;28:69-75
164. Kupersmith M, Martin V, Heller G, Shah A, Mitnick H. Idiopathic Hypertrophic Pachymeningitis. *Neurology* 2004;62:686-694
165. Kalish H, Turtel L, Kupersmith MJ. The natural history of intraocular hemorrhages associated with non-traumatic subarachnoid hemorrhage. *Retina* 2004; 24:36-40
166. Song J, Niimi Y, Brisman J, Fernandez P, Buciu R, Kupersmith M, Berenstein. Thrombus formation during intracranial aneurysm coiling: treatment with intra-arterial abciximab. *Am J Neuroradiol* 2004;7:1147-1153
167. Optic Neuritis Study Group. Neurologic impairment 10 years after optic neuritis. *Arch Neurol* 2004;1386-1389
168. Optic Neuritis Study Group. Long-term magnetic resonance imaging changes after optic neuritis in patients without clinically definite multiple sclerosis. *Arch Neurol* 2004;61:1538-1541
- 2005
169. Kupersmith M, Ying G. Ocular motor dysfunction in ocular myasthenia gravis: effects of treatment. *Br J Ophthalmol* 2005;89:1330-1334

170. Sibgatullah M, Kupersmith M, Zerykier A, Volpe S. Ischemic optic neuropathy after liposuction. *Neuro-ophthalmology* 2005;29:91-93
171. Holmes J, Leske D, Kupersmith M. New methods for quantifying diplopia. *Ophthalmology* 2005;112:2035-2039
172. Stiebel-Kalish H, Kalish Y, Huna Bar-On R, Setton A, Niimi Y, Berenstein A, Kupersmith MJ. Presentation, Natural History and Management of Carotid Cavernous Aneurysms. *Neurosurgery* 2005;57:850-857
- 2006
173. De la Cruz J, Kupersmith M. Clinical profile of simultaneous bilateral optic neuritis in adults. *Br J Ophthalmol* 2006;90:551-554
174. Langer DJ, Song JK, Niimi Y, Chwajol M, Lefton DR, Brisman JL, Molofsky W, Kupersmith MJ, Berenstein A. Transarterial embolization of vein of Galen malformations: the use of magnetic resonance imaging noninvasive optimal vessel analysis to quantify shunt reduction. Report of two cases. *J Neurosurgery* 2006;104(1 Suppl):41-5
175. Kupersmith M, Heller G, Cox Terry. MRA and clinical evaluation of third nerve palsies and posterior communicating artery aneurysms. *J Neurosurg* 2006;105:228-234
176. Berenstein A, Joon S, Niimi Y, Namba K, Brisman J, Heran N, Nahoum M, Madrid M, Kupersmith M. Treatment of Cerebral Aneurysms with Hydrogel-Coated Platinum Coils (Hydrocoil®): Early Single Center Experience. *Am J Neuroradiol* 2006; 27:1834-1840
177. Pro M, Pons M, Liebmann J, Ritch R, Zafar S, Lefton D, Kupersmith M. Imaging of the optic disc and retinal nerve fiber layer in acute optic neuritis. *J Neurol Sci* 2006;250:114-119
- 2007
178. Heran N, Song J, Kupersmith M, Niimi Y, Namba K, Langer D, Berenstein A. Large ophthalmic segment aneurysms with anterior optic pathway compression: Assessment of anatomic and vision outcomes after endosaccular coiling. *J Neurosurg* 2007;106:968-975
179. Kupersmith M, Gal R, Beck R, Xing D, Miller N, The Optic Neuritis Study Group. Visual Function at Baseline and One Month in Acute Demyelinating Optic Neuritis Predicts Visual Outcome. *Neurology* 2007;69:508-514
180. Song J, Kupersmith M. Cerebral Arteriovenous Malformation Postnatal Growth and Development Imaged by Serial MRI in a Child with Hemangiomas. *J Neurosurgery Pediatrics* (In Press)

2008

181. Niimi Y, Kupersmith MJ, Ahmad S, Song J, Berenstein A. Cortical Blindness, Transient and Otherwise, Associated with Detachable Coil Embolization of Intracranial Aneurysms. *AJNR* 2008;29:603-607
182. ONTT Study Group. Optic Neuritis Study Group. Visual Function 15 Years after Optic Neuritis: A Final Follow-up Report from the Optic Neuritis Treatment Trial. *Ophthalmology* 2008;115:1079-1082
183. ONTT Study Group. Multiple Sclerosis Risk after Optic Neuritis: Final Optic Neuritis Treatment Trial Follow Up. *Arch Neurol* 2008; 65:727-732

2009

184. Kupersmith M. Ocular Myasthenia Gravis: Treatment Successes and Failures in Patients with Long Term Follow Up. *J Neurol* 2009;256:1314-1320

2010

185. Lesser R, Knisely J, Wang S, Yu J, Kupersmith. Long term response to fractionated radiotherapy of presumed optic nerve sheath meningioma *Br J Ophthalmol* 2010;94:559-563
186. Keltner J, Johnson C, Cello K, Dontchev M, Gal R, Beck R, Optic Neuritis Study Group. Visual field profile of optic neuritis: a final follow-up report from the optic neuritis treatment trial from baseline through 15 years. *Arch Ophthalmol* 2010;128:330-337

2011

187. Kupersmith M, Mandel G, Anderson S, Meltzer D, Kardon R. Baseline and one month changes in the peripapillary retinal nerve fiber layer in acute optic neuritis: Relation to baseline vision and MRI. *J Neurol Sci* 2011; 308:117-123
188. Kupersmith M, Sibony P, Mandel G, Durbin M, Kardon R. Optical coherence tomography of the swollen optic nerve head: deformation of the peripapillary RPE layer in papilledema *Inv Ophthalmol Vis Sci* 2011;52:6558-6564
189. Sibony P, Kupersmith M, Rohlf FJ. Geometric morphometrics of the peripapillary SD-OCT: Shape analysis of the RPE layer in papilledema and ischemic optic neuropathy. *Invest Ophthalmol Vis Sci* 2011; 52:7987-7995

2012

190. Bruce B, Kupersmith M. Safety of prednisone for ocular myasthenia gravis. *J Neuro-Ophthalmology* 2012; 32:212-215

191. Kupersmith, M, Kardon R, Durbin M, Horne M, Schulman J. Scanning Laser Polarimetry Reveals Status of Axon Integrity in Areas of Optical Coherence Tomography Revealed Thickened Retinal Nerve Fiber Layer (RNFL) with Optic Nerve Head Swelling. *Invest Ophthalmol Vis Sci* 2012;53:1962-1970

192. Wang J, Kardon R, Kupersmith M, Garvin M. Automated Quantification of Volumetric Optic Disc Swelling in Papilledema Using Spectral-Domain Optical Coherence Tomography. *Investigative ophthalmology & visual science*. 2012; 53(7):4069-75

2013

193. Kupersmith M, Anderson S, Kardon R. Predictive value of 1 month retinal nerve fiber layer thinning for deficits at 6 months after acute optic neuritis. *Multiple Sclerosis J* 2013; 19:1743-1748

194. Kupersmith M, Anderson S, Durbin M, Kardon R. Scanning laser polarimetry, but not optical coherence tomography predicts permanent visual field loss in nonarteritic anterior ischemic optic neuropathy. *Inv Ophthalmol Vis Sci* 2013; 54:5414-5419

2014

195. Sibony P, Strachovsky M, Honkanen R, Kupersmith M. Optical coherence tomography shape analysis of the peripapillary retinal pigment epithelium layer in presumed optic nerve sheath meningiomas. *J Neuro-Ophthalmol* 2014;34:130-136

196. Friedman D, McDermott M, Kiebertz K, Kupersmith M, Stoutenberg A, Keltner J, Feldon S, Schron E, Corbett J, Wall M, NORDIC IIHTT Study Group. The Idiopathic Intracranial Hypertension Treatment Trial: Design Considerations and Methods. *J Neuro-Ophthalmol* 2014; 34:107-117

197. Wall M, Kupersmith M, Kiebertz K, Corbett J, Feldon S, Friedman D, Katz D, Keltner J, McDermott M for the NORDIC Idiopathic Intracranial Hypertension Study Group. The Idiopathic Intracranial Hypertension Treatment Trial: Clinical Profile at Baseline. *JAMA Neurology* 2014;71(6):693-701

198. NORDIC Idiopathic Intracranial Hypertension Study Group. The Idiopathic Intracranial Hypertension Treatment Trial: a Randomized Trial of Acetazolamide. *JAMA* 2014;311:1641-1651

199. Keltner J, Johnson C, Cello K, Wall M, NORDIC IIIHTT Study Group. Baseline visual fields findings in the Idiopathic Intracranial Hypertension Treatment Trial (IIHTT). *IOVS* 2014;55:3200-3207

200. OCT Sub-Study Committee for the NORDIC Idiopathic Intracranial Hypertension Study Group. Baseline OCT Measurements in the Idiopathic Intracranial Hypertension Treatment Trial: Part I. Quality Control, Comparisons and Variability. *Inv Ophthalmol Vis Sci*

2014;55:8180-8188

201. OCT Sub-Study Committee for the NORDIC Idiopathic Intracranial Hypertension Study Group. Baseline OCT Measurements in the Idiopathic Intracranial Hypertension Treatment Trial: Part II. Correlations and Relationship to Clinical Features. *Inv Ophthalmol Vis Sci* 2014;55: 8173-8179

Chapters, Review Articles, Editorials:

1. Lieberman A, Neophytides A, Kupersmith M, Casson I, et al: Treatment of Parkinson's Disease with Dopamine Agonists: A Review. *Am J Med Sci* 278:65-76, 1979.
2. Lieberman A, Kupersmith M, Gopinathan G, Estey E, and Goldstein M: "Modification of the "on-off" Effect with Bromocriptine and Lergotrile". *Dopaminergic Ergot Derivatives and Motor Function*. pp.285-295, 1979. Edited by: K. Fuxe, D. Caine, Pergamon Press, Oxford and N.Y.
3. Lieberman A, Estey E, Gopinathan G, Kupersmith M, and Goldstein M: "Bromocriptine and Lergotrile in Parkinson Disease". *Catecholamines Basic and Clinical Frontiers*. pp.1584-1586, 1979. Edited by: E. Usdin, J. Kopin, J. Barchas, Pergamon Press, Oxford and N.Y.
4. Lieberman A, Kupersmith M, Neophytides A, Gopinathan G, Casson I, Durso R, Foo SH, Khayali M, Tartaro T, and Goldstein M: "Bromocriptine in Parkinson's Disease: Report on 106 Patients Treated for Up to 5 Years". *Adv in Biochemical Psychopharmacology* 23:245-253, Raven Press, New York.
5. Lieberman A, Neophytides A, Leibowitz M, Kupersmith M, Pact V, Walker R, Zasorin N, Goodgold A, and Goldstein M: "The Use of Two New Dopamine Agonists: Pergolide and Lisuride in Parkinson's Disease". *Parkinson's Disease - Current Progress, Problems and Management*, pp.335-356, 1980. Edited by U.K. Rinne, M. Klinger, and G. Stamm; Elsevier/North Holland Biomedical Press, 1980.
6. Kupersmith M and Ransohoff J: "Identifying Horner's Syndrome". *Hospital Medicine*, pp.38-39, March 1980.
7. Kupersmith MJ: Angiomatosis Retinae. In *Current Ocular Therapy*, ed. Fraunfelder, F.T., W.B. Saunders, pp.163, 1984.
8. Kupersmith M and Siegel I: "Electrophysiological Evaluation of Retinal Dysfunction in Ophthalmology". *Evoked Potentials*, Williams and Wilkins, ed. Cracco, R.Q. and Bodis-Wollner, I., pp.333-342, 1986.
9. Kupersmith MJ and Siegel I: "Electrophysiological Testing in Neuro-Ophthalmology". *International Ophthalmology Clinics* 26:175-195, 1986.

10. Kupersmith MJ: "Visual Evoked Potential: Enhancing Its Utility". *Seminars in Neurology* Vol 6(2)217-230, 1986.
11. Kupersmith MJ, Seiple WH, and Nelson JI: *Physiological Interpretation of the VER. Highlights in Neuro-ophthalmology* pp.103-114, 1987.
12. Kupersmith MJ: *Bedside Neuro-ophthalmological Exam. Neuro-view, Trends in Clinical Neurology* 3:3-36, 1987.
13. Kupersmith MJ, Shakib M: *The Blood Ocular Barriers. The Clinical Impact of the Blood Brain Barrier and its Manipulation. Plenum Medical Book Co., editor, Ed Neult, 1988.*
14. Kupersmith MJ: *Neuro-ophthalmic Examination: Facial Nerve. American Academy Ophthalmology Basic and Clinical Science Course. Section 5 1988*
15. Kupersmith MJ, Holopigian K, and Seiple WH: "Contrast Sensitivity Testing". In *Press New Methods of Sensory Visual Testing. Sadun A and Wall M (eds)., 1989*
16. Kupersmith MJ: *Visual Evoked Potential. In Biomedical Foundations of Ophthalmology, Vol 2, Chapter 105, JB Lippincott Co. 1990.*
17. Kupersmith MJ: *Tobacco-Alcohol Amblyopia. In The Eye In Systemic Disease. Gold DH, Weingeist TA (eds), Chapter 159, pp 477-479, 1990.*
18. Kupersmith MJ: *Visual Evoked Potential. In Duane's Foundations of Clinical Ophthalmology. Volume 2. Tasman W, Jaeger EA (eds), Chapter 105, JB Lippincott, Philadelphia.*
19. Kupersmith, MJ: *Editorial: Techniques and Surgical Approach for Transvenous Embolization. Arch Ophthalmol 114:750, 1996.*
20. Kupersmith MJ: "Neuro-ophthalmic and Neurological Complications of Ophthalmic Anesthesia". In *Ocular Anesthesia, ed Greenbaum S, W.B. Saunders. 1997, pp. 151-168.*
21. Turbin R, Kupersmith MJ. *Giant cell arteritis. Current Treatment Options in Neurology. 1999;1:49-56*
22. Sadun A, Kupersmith MJ. *Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting, April 29-May 4, 2001. J Neuro-ophthalmol 2001;21:227-230*
23. Niimi Y, Berenstein A, Kupersmith MJ. *Endovascular techniques in the treatment of cavernous sinus aneurysms. In: Eisenberg MB, Ossama AM. The Cavernous Sinus: A Comprehensive Text. Lippincott Williams & Wilkins, Phil. 2000; p 155-176*

24. Bhatti MT, Peters KR. Kupersmith M, Prestigiacomao C. A red eye and then a really red eye. *Surv Ophthalmol* 2003;48:224-229
25. Kupersmith MJ, Lefton DR. Cavernous sinus disorders. In: *Neurological Therapeutics. Principals and Practice.* (ed) Martin Dunitz Publishers, London 003
26. Kupersmith MJ. Does early immunotherapy reduce the conversion of ocular myasthenia gravis to generalized myasthenia gravis? *J Neuro-ophthalmol* 2003;23:249-250

2004

27. Kupersmith MJ. Does early treatment of ocular myasthenia gravis with prednisone reduce progression to generalized disease? *J Neurol Sci* 2004; 123-124

2006

28. Kupersmith, MJ. Are CD MRIs Compatible with Good Neurological Practice? *J Neuroimaging* 2006;16:115-116

2009

29. Kupersmith M, Miller N, Balcer L, Gordon L, Wall M, Keltner J, Friedman D, Feldon S, McDermott M, Kieburz K. The Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC). *J Neuro-Ophthalmol* 2009;29:

Books:

Kupersmith MJ: *Neurovascular Neuro-ophthalmology.* Heidelberg, Springer- Verlag, 1993

Abstracts, Letters, and Presentations:

1973

1. Boshes B, Zeller A, Arbit J, Blonsky ER, Dolkart MA, Stahl S, Kupersmith M: "The Role of Monoamines in the Consolidation of Memory". International Congress of Neurology. Barcelona, Spain, 1973.

1976

2. Lieberman A, Kupersmith M, Vogel B, Goodgold A, Goldstein M: "Treatment of Parkinson's Disease with Bromocriptine". Presented: American College of Clinical Pharmacology, Philadelphia, Pennsylvania, May 1976.
3. Lieberman A, Kupersmith M, Estey E, Goldstein M: "Lergotriple in Parkinson's Disease". *Lancet* 1:515-516, 1976 (Letter).

1977

4. Lieberman A, Estey E, Kupersmith M, Gopinathan G, Goldstein M: "Treatment of Parkinson's Disease with Lergotriple Mesylate". Presented: American Academy of Neurology, Atlanta, Georgia, April 1976. *Neurology* 27:1977 (Abstract).

1978

5. Kupersmith M: "The Pathophysiology of Neurotransmitters in Involuntary Movement Disorders". Presented: Maine Medical Center, September, 1978.
6. Lieberman A, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M: "Lergotriple in Parkinson's Disease: Further Studies". Presented: 28th Annual Meeting, American Academy of Neurology, Los Angeles, California, April 1978.
7. Lieberman A, Gopinathan G, Estey E, Kupersmith M, Goodgold A, Goldstein M: "Bromocriptine in Parkinson's Disease: Further Studies". Presented: 28th Annual Meeting, American Academy of Neurology, Los Angeles, California, April 1978.
8. Lieberman A, Kupersmith M, Gopinathan G, Estey E, Goldstein M: "Modification of the "On-Off" Effect with Bromocriptine and Lergotriple". Presented: International Symposium on Dopaminergic Ergot Derivatives and Motor Function. Wenner-Gren Center, Stockholm, Sweden, July 1978.
9. Lieberman A, LeBrun Y, Zolfagharj M, Hassouri M, Kupersmith M, Estey E, Gopinathan G: "Parkinson Disease: Clinical Evaluation".
10. Lieberman A, Estey E, Gopinathan G, Kupersmith M, Goldstein M: "Bromocriptine and Lergotriple in Parkinson's Disease". Presented: Fourth International Catecholamine Symposium. Asilomar Conference Center, Pacific Grove, California, September, 1978.
11. Lieberman A, Kupersmith M, Casson I, Durso R, Foo SH, Khayali M, Tartaro T: "Bromocriptine and Lergotriple: Comparative Efficacy in Parkinson's Disease. Quebec City, Quebec, September 1978.
12. Lieberman A, Dziatolowski M, Kupersmith M, Aleksic S, Serby M, Korein J, Goldstein M: "The Dementias of Huntington's and Parkinson's Disease". Symposium on Huntington's Disease, San Diego, California, November 1978.

1979

13. Lieberman A, Leibowitz M, Neophytides A, Kupersmith M, Mehl S, Kleinberg D, Serby M, Goldstein M: "Pergolide and Lisuride for Parkinson's Disease". *Lancet* 11:1129-1130, 1979 (Letter).
14. Lieberman A, Kupersmith M, Neophytides A, Casson I, Durso R, Foo SH, Khayali M,

Goldstein M: "Long-Term Efficacy of Bromocriptine in Parkinson's Disease". Presented: 31st Annual Meeting, American Academy of Neurology. Chicago, Illinois, April 26-28, 1979.

15. Dziatolowski M, Lieberman A, Kupersmith M, Serby M, Goodgold A, Korein J, Goldstein M: "Dementia in Parkinson's Disease". Presented: International Symposium Ergot Alkaloids. New York, N.Y., May 10-11, 1979.

1980

16. Lieberman A, Neophytides A, Leibowitz M, Kupersmith M, Walker R, Zasorin N, Pact V, Goldstein M: "The Efficacy of a Potent Dopamine Agonist, Lisuride, in Parkinson's Disease". Presented: 32nd Annual Meeting of the American Academy of Neurology. New Orleans, Louisiana, April 28 - May 3, 1980.
17. Lieberman A, Leibowitz M, Neophytides A, Kupersmith M, Pact V, Walker R, Zasorin N, Goldstein M: "The Efficacy of a Potent Long-Acting Dopamine Agonist, Pergolide, in Parkinson's Disease. Presented: 32nd Annual Meeting of the American Academy of Neurology. New Orleans, Louisiana, April 28-May 3, 1980.
18. Siegel IM, Kupersmith MJ: "Dissociation of VEP and Subjective Acuity in Chiasmal Gliomas". Presented: Association for Research in Vision and Ophthalmology. Orlando, Florida, May 5-9, 1980.
19. Lieberman AN, Neophytides A, Leibowitz M, Kupersmith M, Walker R, Zasorin N, Kleinberg D, Goldstein M: "Lisuride in Parkinson Disease". Presented: 81st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. San Francisco, California, March 19-21, 1980.
20. Lieberman A, Leibowitz M, Kupersmith M, Neophytides A, Pact V, Mehl S, Kleinberg D, Goldstein M: "Pergolide in Parkinson Disease". Presented: 81st Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics. San Francisco, California, March 19-21, 1980.
21. Kupersmith MJ, Shakin E, Siegel I, Carr R, Ransohoff J: "Visual Evoked Potentials in Optic Chiasm Gliomas". Presented: 48th Meeting, American Association of Neurological Surgeons. New York, New York, April 20-24, 1980.
22. Kupersmith MJ: "Visual Evoked Potentials in Optic Chiasm Gliomas". Presented: New York Academy of Medicine, may 19, 1980.
23. Kleinberg DL, Lieberman A, Todd J, Meddick J, Neophytides A, Kupersmith M: "Twenty Four Hour Suppression of Prolactin by Pergolide Mesylate, A New Ergot Drug". Presented: The Endocrine Society, Washington, D.C., June 1980.
24. Kupersmith MJ, Siegel I, Carr R: "Reduced Contrast Sensitivity in Compressive Lesions of the Anterior Visual Pathway". Presented: American Academy of Ophthalmology,

November 5, 1980.

1981

25. Kleinberg DL, Greising J, Ragavan V, Seltzer T, Kricheff I, Kupersmith M, Flamm E: "Twenty Four Hour Prolactin Suppression and Pituitary Tumor Shrinkage by Pergolide". Presented: The Endocrine Society. Cincinnati, Ohio, June 1981.
26. Kupersmith MJ: "Anatomical and Physiological Basis for Understanding the VEP". Presented: The New York Academy of Medicine. White Plains, New York, March 7, 1981.
27. Kupersmith MJ: "Cavernous Optic Atrophy with Suprasellar Lesions". Presented: The New York Glaucoma Round Table. New York, N.Y., April 22, 1981.
28. Kupersmith MJ: "Visual Evoked Potential in Neuro-Ophthalmological Disorders". Presented: The New York Ophthalmology Society. New York, New York, May 11, 1981.
29. Lieberman A, Goldstein M, Neophytides A, Leibowitz M, Gopinathan G, Kupersmith MJ: "Further Studies with Lisuride, a Potent Dopamine and Serotonin Agonist in Patients with Parkinson's Disease Who are No Longer Satisfactorily Responding to Levodopa". Presented: American Society for Clinical Pharmacology and Therapeutics. New Orleans, Louisiana, March 19-21, 1981.

1982

30. Nelson JI, Kupersmith MJ, Seiple W, Weiss P, Carr R: "Neurophysiological Investigation of the 20/20 Eye in Multiple Sclerosis". Presented: ARVO, 1982.
31. Kupersmith M: "VEP's in Neuro-Ophthalmology". Presented at Continuing Education Course in Ophthalmic Electrodiagnosis. Sponsored by Tufts University School of Medicine and New England Medical Center, The Parker House, Boston, Massachusetts, March 4-5, 1982.
32. Kupersmith MJ, Berenstein A, Flamm E, Ransohoff J: "Neuro-Ophthalmologic Abnormalities and Percutaneous Transvascular Treatment of Giant Aneurysms of the Cavernous Carotid Artery". Presented: 34th Annual Meeting of the American Academy of Neurology, Sheraton Washington Hotel, Washington, D.C., April 25- May 1, 1982.
33. Kupersmith MJ: "Visual Evoked Potential". Presented: 55th Annual New York Eye and Ear Infirmary Clinical Conference. Sponsored by the Post Graduate Institute and New York Eye and Ear Infirmary Staff and Alumni, Marriott's Essex House, New York City, May 13-14, 1982.
34. Kupersmith MJ, Berenstein A, Choi IS: "The Evaluation of Transvascular Therapy of

Intracavernous Carotid Aneurysms and Carotid-Cavernous Sinus Fistulas". Presented: Fourth Meeting of the International Society of Neuro-ophthalmology, Princess Hotel, Bermuda, June 12-17, 1982.

35. Kupersmith MJ, Krohn D: "Cavernous Optic Atrophy with Compressive Lesions of the Anterior Visual Pathway". Presented: 107th Annual Meeting of the American Neurological Association, Washington Hilton Hotel, Washington, D.C., September 30 - October 2, 1982.
36. Nelson JI, Kupersmith MJ, Seiple WH, Carr RE: "The Swept Display Technique: Separation of X- and Y- Dominated Evoked Potentials". Presented: 2nd International Evoked Potentials Symposium. Sponsored by the Cleveland Clinic Foundation and The Biological Engineering Society, Stouffer's Inn on the Square, Cleveland, Ohio, October 18-20, 1982.
37. Price MJ, Seiple WH, Kupersmith MJ, Siegel IM, Carr RE: "The Pattern Electroretinogram in the Assessment of Optic Nerve Disease". Presented: American Academy of Ophthalmology.
38. Kupersmith MJ: "Visual Evoked Potentials in Neurological Diseases". Presented: Continuing Education Course, Advanced Procedures in Clinical Electrodiagnosis of Neuromuscular Diseases. Sponsored by the New York University Medical Center and The Institute of Rehabilitation Medicine, New York University Medical Center, December 8-10, 1982.
39. Berenstein A, Ransohoff J, Kupersmith MJ, Flamm E, Graeb D, Kricheff I. Endovascular Treatment of Giant Aneurysms of the Carotid and Vertebral Arteries. Functional Investigation and Embolization. 12th Symposium Neuroradiologicum, Washington, D.C., October 10-16, 1982.

1983

40. Kupersmith MJ: "Bilateral Adie's Pupil". Presented: Frank Walsh Society Annual Meeting, New Orleans, February 26, 1983.
41. Kupersmith MJ: "Visual Evoked Potentials: Neuroanatomy, Normative Data, Applications and Shortcomings". Presented: Sensory Evoked Potentials: A Workshop Symposium, Kingsbrook Jewish Medical Center, January 12, 1983.
42. Kupersmith MJ: "Performance and Interpretation of Visual Evoked Potentials". Presented at the Third Annual Workshop on Evoked Potentials, White Plains, N.Y., March 18-20, 1983.
43. Kupersmith MJ, Nelson JI, Seiple WH, and Carr RE: "Rapid Visual Assessment from Evoked Potentials: An Alternative to Computer Averaging". Presented at the Rocky Mountain Neuro-Ophthalmology Society Symposium on Disorders of the Visual System,

February 16-19, 1983.

44. Kupersmith MJ: "Contrast Sensitivity Determinations in Ophthalmology". Presented at the Manhattan Ophthalmology Society, January 17, 1983.
45. Kupersmith MJ: "Does Electrophysiologic Testing Have a Role in the Diagnosis of Optic Neuropathies?" American Academy of Ophthalmology, Northeast Regional Update Course, Philadelphia, April 9, 1983.
46. Seiple WH, Kupersmith MJ, and Carr RE: "The Evaluation of Optic Nerve Disease Using the Pattern Electroretinogram". American Academy of Neurology, April 24-30, 1983, San Diego.
47. Kupersmith MJ, Seiple WH, Nelson JI, and Carr RE: "VEP Defined Orientation Losses in Multiple Sclerosis". Presented at ARVO Annual Spring Meeting, Sarasota, Florida, May 1-6, 1983.
48. Nelson JI, Kupersmith MJ, Seiple WH, and Carr RE: "VEP Demonstration of the Oblique Effect". Presented at the ARVO Annual Spring Meeting, Sarasota, Florida, May 1-6, 1983.
49. Kupersmith MJ, Nelson JI, and Carr RE: "The Visual Evoked Potential as a Prognosticator in Childhood Cortical Blindness". American Neurological Association 108th Annual Meeting, New Orleans, October 4, 1983.
50. Kupersmith MJ, Nelson JI, Seiple W, and Carr RE: "Evoked Potential-Defined Orientation-Specific Losses in Multiple Sclerosis". American Neurological Association 108th Annual Meeting, New Orleans, October 4, 1983.
51. Nelson JI, Seiple WH, Kupersmith MJ, and Carr RE: "Rapid Visual Evoked Potential Index of Cortical Adaptation". Society for Neuroscience Annual Meeting, Boston, November 8, 1983.
52. Kupersmith MJ, Nelson JI, Seiple WH, and Carr RE: "Electro-physiological Confirmation of Orientation-Specific Contrast Losses in Multiple Sclerosis". Conference on Multiple Sclerosis: Theory and Practice, New York Academy of Sciences, New York, N.Y., November 29-December 1, 1983.
53. Kupersmith M, Nelson J, Seiple W, and Carr R: "Rapid Visual Assessment from the Evoked Potential: An Alternative to Computer Averaging". 37th Annual Meeting Eastern Association of Electroencephalographers, St. Vincent's Hospital, New York, December 1, 1983.

1984

54. Kupersmith MJ, Nelson JI, Seiple WH: "Rapid Visual Assessment from Visual Evoked Potentials: An Alternative to Computer Averaging". Rocky Mountain Neuro-

Ophthalmology Society, Symposium on Disorders of the Visual System, Utah, January 17-20, 1984.

55. Seiple WH, Kupersmith MJ: "The Evaluation of Optic Nerve Disease Using the Pattern Electroretinogram". Rocky Mountain Neuro-Ophthalmology Society, Symposium on Disorders of the Visual System, Utah, January 17-20, 1984.
56. Warren FA, Kupersmith MJ: "An Unusual Case of an Adie's Pupil". The Frank B. Walsh Society, 16th Annual Meeting, Cleveland, Ohio, February 24-25, 1984.
57. Kupersmith MJ: "Management of Vascular Lesions of the Cavernous Sinus". Neuro-Ophthalmology Meeting, Manhattan Eye and Ear Hospital Conference, March 3, 1984.
58. Kupersmith MJ: "Visual Evoked Potentials". American Society for Clinical Evoked Potential. Washington, D.C., March 30, 1984.
59. Nelson JI, Kupersmith MJ, Seiple WH: "Visual Evoked Response Measurement of Cortical Adaptation". American Academy of Neurology, 36th Annual Meeting, Boston, Massachusetts, April 10-12, 1984.
60. Nelson JI, Seiple WH, Kupersmith MJ, and Carr RE: "Rapid Visual Evoked Potential Index of Cortical Adaptation". Presented at the ARVO Annual Spring Meeting, Sarasota, Florida, April 30-May 4, 1984.
61. Kupersmith MJ, Seiple WH, and Nelson JI: "Retrolbulbar Neuritis: Loss of Cortically Mediated Visual Function". Presented at the ARVO Annual Spring Meeting, Sarasota, Florida, April 30-May 4, 1984.
62. Kupersmith MJ, Seiple WH, and Nelson JI: "VEP Defined Orientation-Specific Contrast Losses in Retrolbulbar Neuritis and Multiple Sclerosis". Presented at the Joint World Meeting Neuro-ophthalmology, Antwerp, Belgium, May 14-18, 1984.
63. Kupersmith MJ, Warren FA, Newall J, and Ransohoff J: "Radiation of Intracranial Anterior Visual Pathway Meningiomas". Presented at the 109th Annual Meeting of the American Neurological Association, Baltimore, Maryland, October 7-10, 1984.
64. Kupersmith MJ, Warren FA, and Berenstein A: "Embolization of Spontaneous Vascular Shunts Involving the Cavernous Sinus". American Academy of Ophthalmology, Atlanta, GA, November 11-15, 1984.

1985

65. Cohen A, Cooper P, Kupersmith M, Flamm E, and Ransohoff J: "Visual Recovery Following Transphenoidal Resection of Pituitary Adenomas". American Association of Neurological Surgeons 1985 Annual Meeting, Atlanta.
66. Kupersmith M, Frohman L, Carr R, Wise A, Foo SH, Ransohoff J, and Choi I: "Visual Dysfunction Related to Intra-Arterial Chemotherapy for Gliomas". AAN 37th Annual

- Meeting, Dallas, Texas, 1985.
67. Kupersmith MJ, Seiple WH, and Nelson JI: "Evoked Potential Assessment and Cortical Adaptation: Studies with Dopaminergic Agents and In Epilepsy". AAN 37th Annual Meeting, Dallas, Texas, 1985.
 68. Kupersmith MJ: "50 Cases of Complicated Migraine". Presented at the Rocky Mountain Neuro-Ophthalmology Society Meeting, Banff, March 6-9, 1985.
 69. Kupersmith MJ: "Escape From Bromocriptine". Presented at the Rocky Mountain Neuro-Ophthalmology Society Meeting, Banff, March 6-9, 1985.
 70. Kupersmith MJ: "The Visual Evoked Potential in Multiple Sclerosis". Presented at the Rocky Mountain Neuro-Ophthalmology Society Meeting, Banff, March 6-9, 1985.
 71. Kupersmith M, Frohman L, Kleinberg D, Budzilovich G, Cooper P, and Ransohoff J: "Escape From Bromocriptine". Presented at the 110 Annual Meeting of the American Neuro-logical Association, Chicago, Illinois, October 2-5, 1985.
 72. Kupersmith MJ, Weinberg H, Frohman L, Warren F, and Breinin G: "Ocular Myasthenia: Diagnosis and Treatment". Presented at the 110th Annual Meeting of the American Neurological Association, Chicago, Illinois, October 2-5, 1985.
 73. Kupersmith MJ: "Visual Evoked Potentials: State of the Art". Presented at the American Society for Clinical Evoked Potentials, Orlando, Florida, March 22, 1985.
 74. Kupersmith MJ: "Optic Gliomas in the Pediatric Patient". Presented at the 58th Annual New York Eye and Ear Infirmary Clinical Conference, New York, N.Y., March 28-29, 1985.
 75. Lang J, Frohman L, Reede D, Kupersmith M, Bergeron R, and Trasi S: "Pseudotumor of the Orbit with Bone Changes and Intracranial Extension". ASNR, February 18, 1985.
 76. Kupersmith MJ: "Myelopathy and Visual Loss". Presented at the Frank B. Walsh Society Meeting, Baltimore, Maryland, February 22-23, 1985.
 77. Wertebaker C, Kupersmith M, and Behrens M: Letters to the Editor - Monocular Blindness with Preserved Pupillary Reflexes. Arch Neurol 42:515, June 1985.
- 1986
78. Kupersmith M: "Misdiagnosis of Wernicke's". Presented at the Frank B. Walsh Society 18th Annual Meeting, Seattle, Washington, February 22, 1986.
 79. Kupersmith M: "Intra-Arterial Chemotherapy for Gliomas". Presented at the 12th Annual Rocky Mountain Neuro-ophthalmology Course, Whistler Resort, B.C., February 27, 1986.

80. Kupersmith M: "Visual Evoked Potentials - State of the Art". Presented at the 6th Annual Conference on Evoked Potentials, San Juan Convention Center, March 2-7, 1986.
 81. Kupersmith M, Burde R, Klingele T, et al: "Autoimmune Optic Neuritis: Masquerading as MS". Presented at the 38th Annual Meeting of the American Academy of Neurology, New Orleans, Louisiana, April 27-May 3, 1986.
 82. Kupersmith MJ, Frohman L, Warren F, and Pinto R: "Diagnosis and Treatment of Unusual Disorders of the Chiasm". Presented at the American Neurological Association, Boston, Massachusetts, October 5-8, 1986.
 83. Kupersmith MJ, Seiple WH, and Nelson JI: "Physiological Interpretation of the VER". Presented at the 6th International Neuro-ophthalmology Society (INOS) Congress in Hakone, Japan, June 9-16, 1986.
 84. Frohman LP, Pinto R, Warren F, and Kupersmith M: "Metrizamide Computed Tomographic Cisternography: Procedure of Choice for Chiasmal Syndromes with Equivocal CT Scans". Presented at the American Academy of Ophthalmology. Ophthalmology Vol 93 No 8 Supplement.
- 1987
85. Kupersmith MJ: "Complications of Embolization of Cavernous Sinus Vascular Lesions". Presented at the North American Neuro-Ophthalmology Society, Lake Tahoe, February 1-5, 1987.
 86. Kupersmith MJ, Choi IS, Berenstein A, Warren FA, and Gelwan M: "Management of Spontaneous Vascular Shunts Involving the Cavernous Sinus". Presented at the American Academy of Neurology, New York, N.Y., April 5-11, 1987.
 87. Bass SJ, Fleming M, Sherman J, and Kupersmith MJ: "Effect of Stimulus Orientation on the VEP in Moderate and High Astigmatism". Invest Ophthalmol Vis Sci 28:305, 1987.
 88. Brussell EM, Kupersmith M, and Dixon M: "Flicker Resolution at 5 Hz as a Function of Age". Invest Ophthalmol Vis Sci 28:218, 1987.
 89. Kupersmith M, Carlow T, Corbett J, et al: Letters to the Editor, Archives of Neurology, Vol 44, February 1987.
 90. DeLeon M, Kupersmith MJ, Miller J, Ferris S, and Wolf A: VEP and PET in Alzheimer's Disease. Invest Ophthalmol Vis Sci 28:304, 1987.
- 1988
91. Kupersmith MJ, Seiple WH, and Holopigian K: "Neurophysiology of Vision". Presented at NANOS, Colorado, February 21-25, 1988.

92. Kupersmith MJ, Burde RM, Gelwan M, and Kellen RI: "Anterior Visual Pathway Sarcoid - Successes and Failures". Presented at the AAN, Cincinnati, April 17-23, 1988. *Neurology* 38:201, 1988.
93. Kupersmith M: "Dopaminergic Modulation of Human Retinal Function". Presented at ISCEV Western Hemisphere Meeting, Sarasota, Florida, May 1, 1988.
94. Diamond GA, Warren FA, Miller DH, Marks C, and Kupersmith M: "Steroid Responsive Optic Neuropathy". Presented at the Frank Walsh Society, Vancouver, May 7-8, 1988.
95. Kupersmith M: "Visual Evoked Potentials". Presented at ASCEP, New York City, May 13-14, 1988.
96. Seiple WH, Holopigian K, Kupersmith MJ, and Mehaffey L: Phase Considerations in the Contrast Swept VEP. *Invest Ophthalmol Vis Res* 29:329, 1988.
97. Holopigian K, Seiple WH, and Kupersmith MJ: Threshold and Suprathreshold Contrast Deficits in Amblyopes. *Invest Ophthalmol Vis Res* 29:77, 1988.

1989

98. Berenstein A, Choi IS, Kupersmith M, Flamm E: Complications of endovascular embolization in 182 patients with cerebral AVMs. Presented at ASNR, March 1989.
99. Kupersmith M: Occipital Lobe Trauma. Presented at the 15th Annual North American Neuro-Ophthalmology Society Meeting, Krystal Hotel, Cancun, Mexico, March 6-10, 1989.
100. Gupta K, Kupersmith M, Seiple W, and Holopigian K: Optic atrophy fails to alter the electroretinogram. Presented at ARVO Sarasota, Florida, April 30-May 5, 1989.
101. Kupersmith MJ: Evaluation and Treatment of Diplopia - Myasthenia Gravis. Presented at the American Academy of Ophthalmology Annual Meeting, New Orleans, October 29-November, 1989.
102. Rush S, Kupersmith M, Warren F, Cooper P, Ransohoff J, and Newall J: Radiation of Pituitary Macroadenomas. Presented at the American Academy of Neurology 41st Annual Meeting, Hyatt Regency Chicago, April 13-19, 1989.

1990

103. Kupersmith M: Vascular Anatomy of the Cavernous Sinus and Involved Cranial Nerves. Presented at the North American Neuro-Ophthalmology Society Meeting, Feb 4-8, 1990.

104. Warren FA, Kupersmith M, Charles N, Green WR, and Kellogg FR: Rapid Bilateral Visual Loss with Late Skin Problems. Presented at the Frank Walsh Society 22nd Annual Meeting, Indianapolis, Indiana, February 16-17, 1990.
 105. Capo H, Kupersmith MJ, Warren FA: Third Cranial Nerve Palsy: Management Controversy. Presented at the American Academy of Neurology 42nd Annual Meeting Program, Fountainbleu Hilton Hotel, Miami Beach, Florida, April 30-May 6, 1990.
 106. Frohman L, Kupersmith MJ, Warren FA: Letters to the Editor- The Pituitary Incidentaloma Beyond the First Year of Follow up. JAMA 264:2387, 1990.
 107. Kupersmith MJ and Ritch R: Non-glaucomatous optic neuropathy does not predispose to glaucomatous damage from elevated intra-ocular pressure. Presented at the ARVO Annual Meeting, Sarasota, Florida, April 29-May 4, 1990.
 108. Optic Neuritis Study Group: Visual Field Reading Center Optic Neuritis Treatment Trial. Presented at the ARVO Annual Meeting, Sarasota, Florida, April 29-May 4, 1990.
 109. Kupersmith MJ: Immunotherapy of the optic neuritis and autoimmune optic neuritis. Presented at UMD of New Jersey Immunologic Disorders of the Visual System, Bally's Grand Hotel, Atlantic City, N.J., May 7-8, 1990.
 110. Kupersmith MJ: Neurologic and ocular manifestations of sarcoidosis. Presented at UMD of New Jersey Immunologic Disorders of the Visual System, Bally's Grand Hotel, Atlantic City, N.J., May 7-8, 1990.
- 1991
111. Warren FA, Kupersmith MJ: Sixth Nerve Palsy Revisited (Neurosarcoidosis). Presented at the Frank Walsh Society, Salt Lake City, Utah, Feb 21-22, 1991.
 112. Kupersmith M, Seiple W, Holopigian K, Hiesiger E, Warren F: Maculopathy caused by intra-arterial chemotherapy. NANOS, Park City, Utah, Feb. 24-28, 1991.
 113. Kupersmith MJ, Hurst R, Choi IS, Berenstein A, Jafar J, and Ransohoff J: The benign course of cavernous carotid aneurysms. Neurology 41(Suppl 1):367, 1991.
 114. Kupersmith M, Seiple W, Holopigian K, Noble K, Hiesiger E, and Warren F: Maculopathy caused by chemotherapy. Invest Ophthalmol & Vis Sci 32(4):690, 1991.
 115. Frohman L, Bielory L, Warren F, Bystryn J, Kupersmith M: Skin biopsies in the evaluation of atypical optic neuropathies. Invest Ophthalmol & Vis Sci 32(4):951, 1991.
 116. Clewner L, Holopigian K, Seiple W, Angrist B, Kupersmith M: Dopamine blockade has no effect on the human flash ERG. Invest Ophthalmol & Vis Sci 32(4):1229, 1991.

117. The Optic Neuritis Study Group: Visual Field Reading Center-Optic Neuritis Treatment Trial. ARVO Annual Meeting, Sarasota, FL, April 28-May 3, 1991.

1992

118. Kupersmith MJ, Berenstein A, Vargas M, Warren F, & Hoyt W: Brain AVMs do not cause transsynaptic degeneration in the visual system. NANOS, San Diego, CA, Feb. 23-27, 1992

119. Warren FA, Vargas ME, Seidman I, & Kupersmith MJ: Homonymous field defect in a HIV negative, at risk individual. Frank Walsh Society 24th Annual Meeting, Los Angeles, CA, Feb. 28-29, 1992.

120. Keltner J, Johnson CA, Spurr J, Beck RW, Cleary PA, and the Optic Neuritis Study Group: Recurrent visual field loss in the Optic Neuritis Treatment Trial. ARVO Annual Meeting, Sarasota, FL, May--May 8, 1992.

121. Xin D, Kupersmith MJ, Holopigian K, Seiple WH: VEP amplitude and phase changes following discrete contrast steps. ARVO Annual Meeting, Sarasota, FL, May 3-May 8, 1992.

122. Kupersmith MJ, Beck RW, Cleary PA, and the Optic Neuritis Study Group: Visual deficits in fellow eyes of patients with unilateral optic neuritis: Results of the Optic Neuritis Treatment Trial. ARVO Annual Meeting, Sarasota, FL, May 3 - May 8, 1992.

123. Beck RW, Cleary PA, and the Optic Neuritis Study Group: Normative data for the Pelli-Robson contrast sensitivity chart and for visual acuity in young adults. ARVO Annual Meeting, Sarasota, FL, May 3 - May 8, 1992.

124. Chrousos G, Kettah JC, Beck RW, Cleary PA, and the Optic Neuritis Study Group: Side effects of corticosteroid therapy: Experience of the Optic Neuritis Treatment Trial. ARVO Annual Meeting, Sarasota, FL, May 3 - May 8, 1992.

125. Cleary PA, Beck RW, and the Optic Neuritis Study Group: Intercorrelation of visual function measures in optic neuritis: Experience of the Optic Neuritis Treatment Trial (ONTT). ARVO Annual Meeting, Sarasota, FL, May 3 - May 8, 1992.

126. Warren FA, Vargas EM, and Kupersmith MJ: Exotropia as a sign of myasthenia gravis in dysthyroid ophthalmopathy. International Society of Neuro-Ophthalmology, June 28-July 3, 1992, Williamsburgh, Virginia.

1993

127. Kupersmith MJ, et al: Maculopathy caused by intra-arterially administered cisplatin and intravenously administered carmustine. Ophthalmology Digest, January 1993.

128. Kupersmith MJ, Vargas M, Warren F, Berenstein A. Mechanism for retinal/choroidal visual loss with cavernous sinus arteriovenous shunts. NANOS annual meeting, Big Sky, February 6-10, 1993.
129. Katz B, Beck RW, Kupersmith MJ, et al: Abnormalities of the fellow eye in acute unilateral optic neuritis. Noninvasive Assessment of the Visual System, Eighth Topical Meeting, Doubletree Hotel, Monterey, CA, February 21-23, 1993.
130. Warren F, Kupersmith MJ. Frank Walsh Society, New York, March 13-14, 1993
131. Kupersmith MJ, Kleinberg D. AAN, New York, May 1993
132. Vargas M, Berenstein A, Jafar J, Setton A, Nelson K, Kupersmith MJ, AAN, New York, May 1993
133. Trobe J, Kupersmith MJ, Beck R. One-year. AAN, New York, May 1993
134. Kupersmith MJ, ARVO, Sarasota, May 1993
135. Xin D, Kupersmith MJ, ARVO, Sarasota, May 1993
136. Kupersmith MJ, Berenstein A, Jafar JJ: Which Cavernous Sinus Aneurysms Should be Treated? - Response to Editorial, J Neurosurg 78:1009, June 1993.
- 1994
137. Pak S, Kupersmith MJ, Holopigian K, Seiple W: Visual Loss Caused by Retinal/Choroidal Lesions Associated with Cavernous Sinus Region AV Shunts. Investigative Ophthalmol & Visual Science 35:1374, March 15, 1994.
138. Kupersmith MJ, Nelson PK: Venous Hypertension as the Cause of Occipital Dysfunction. Investigative Ophthalmol & Visual Science 35:1545, March 15, 1994.
139. Bose S, Warren F, Kupersmith MJ: Bilateral Inflammatory Optic Neuropathy: Factors Predicting Visual Recovery. Investigative Ophthalmol & Visual Science 35:2059, March 15, 1994.
140. MacKey CJ, Gouras P, Roy M, Saeki M, Kupersmith MJ, Odell J: Paraneoplastic Cone Dystrophy. Investigative Ophthalmol & Visual Science 35:2119, March 15, 1994.
141. Setton A, Kupersmith MJ, Marino EV, Yashar A, Madrid M, Nelson PK, Berenstein A: Occipital AVMs: Visual Disturbances, Hemorrhages, Treatment. Neurology 44(4):A266, April 1994.
142. Nelson PK, Kupersmith MJ, Setton A, Berenstein A: Visual Symptoms of Dural AVMs

- Draining Into Occipital Veins. *Neurology* 44(4):A266, April 1994.
143. Berenstein A, Siller KA, Setton A, Nelson PK, Levin DN, Kupersmith M: Intra-Arterial Urokinase for Acute Ischemic Stroke During Interventional Neuroradiological Procedures. *Neurology* 44(4):A356, April 1994.
144. Rios RJ, Odel JG, Camac A, Thirkill CE, Lovelace RE, MacKay C, Gouras P, Goei SL, Behrens MM, Kupersmith MJ: A 45 Year Old Female With Guillain-Barre' and Optic Neuritis. Presented at the 26th Annual Frank B. Walsh Meeting, Chicago, IL, April 9-10, 1994.
145. Kupersmith MJ. Letters to the editor, reply from author. Megadose steroids in multiple sclerosis. *Neurology* 44, October 1994.
146. Kupersmith MJ and Kleinberg D: Letters to the editor, reply from authors, December 4, 1994.
- 1995
147. Kupersmith MJ, Bhuiyan S, Warren F, Moster M: Beneficial Effects of Corticosteroids on Ocular Myasthenia. Presented at Association for Vision and Research Meeting, Ft. Lauderdale, FL, May 19, 1995. *Invest Ophthalmol & Visual Science* 36(4), March 15, 1995.
148. Bhuiyan S, Kupersmith MJ, Frohman L, Warren F, et al: Visual Outcome of Treated Sarcoid Optic Neuropathy. Presented at Association for Vision and Research Meeting, Ft. Lauderdale, FL, May 19, 1995. *Invest Ophthalmol & Visual Science* 36(4), March 15, 1995.
149. Sanderson M, Kupersmith MJ, Frohman L, Jacobs J, Hirschfeld J, Ku C, Warren F: Aspirin Reduces Anterior Ischemic Optic Neuropathy (AION) in the Second Eye. Presented at Association for Vision and Research Meeting, Ft. Lauderdale, FL, May 19, 1995. *Invest Ophthalmol & Visual Science* 36(4), March 15, 1995.
150. Kupersmith MJ, Bhuiyan SK, Warren FA, Weinberg H: Corticosteroids Reduce Progression in Ocular Myasthenia Gravis. Presented at the American Academy of Neurology Annual Meeting, Seattle, Washington, May 6-13, 1995.
151. Sanderson M, Kupersmith MJ, Frohman L, Jacobs J, Hirschfeld J, Ku C, Warren F: Aspirin Reduces Anterior Ischemic Optic Neuropathy (AION) in the Second Eye. Presented at the American Academy of Ophthalmology Annual Meeting, Atlanta, GA, October 29-November 2, 1995.
152. Kupersmith MJ, Miller NR: Neurovascular Neuro-Ophthalmology. Presented at the American Academy of Ophthalmology Annual Meeting, Atlanta, GA, October 29-November 2, 1995.

1996

153. Kupersmith MJ, Kazam E, Zweifach P: Orbital Blood Flow in Giant Cell Arteritis. Invest Ophthalmol Vis Sci , 1996.
154. Rosenberg M, Huna R, Warren F, Kupersmith MJ: Unilateral Papilledema Due to Increased Intracranial Pressure. Invest Ophthalmol Vis Sci , 1996.
155. Yang S, Huna R, Kupersmith MJ: Cerebral Polyopia - Neuroimaging Localization. Invest Ophthalmol Vis Sci , 1996.
156. Turbin R, Kupersmith MJ, Langer R, Gemel L, Paget S, Mitnick H, Spiera H: Systemic Corticosteroids Do Not Adversely Affect Vision in the Elderly. Invest Ophthalmol Vis Sci 1996.
157. Huna R, Kupersmith MJ: Pseudotumor Cerebri in Pregnancy: Course, Management, Outcome. Invest Ophthalmol Vis Sci , 1996.
158. Gamell L, Turbin R, Spiegel P, Wall M, Kupersmith MJ: Weight Loss Affects the course of Pseudotumor Cerebri. Invest Ophthalmol Vis Sci 37,S712,1996.

1997

159. Kupersmith MJ, Gamell L, Turbin R, Spiegel P, Wall M. Effect of weight loss on pseudotumor cerebri in women. Neurology 1997; 48:A386
160. Kupersmith MJ for the ONTT. The optic neuritis treatment trial: five year neurologic follow-up results. NANOS, Keystone, Colo, February 10,1997
161. Kupersmith MJ for the ONTT. The optic neuritis treatment trial: five year visual function follow-up results. NANOS, Keystone, Colo, February 10,1997
162. Kupersmith MJ. Visual outcome in patients with giant cell arteritis after one year of therapy. NANOS, Keystone, Colo, February 11,1997
163. Andracchi S, Kupersmith MJ, Nelson P, Slakter J, Setton A, Berenstein A. Visual loss from arterial steal in patients with maxillofacial AVM. Invest Ophthalmol Vis Sci 1997;38:S116
164. Kupersmith MJ, Langer R, Paget S, Mitnick H, Speira H. Visual outcome in patients with giant cell arteritis after 1 year of therapy. Invest Ophthalmol Vis Sci 1997; 38:S970
165. Kupersmith MJ, Langer R, Paget S, Mitnick H, Speira R, Speira H. Outcome in patients with giant cell arteritis after one year of therapy. AAO, San Francisco, October 29, 1997

1998

166. Kupersmith, MJ. Long term experience with cavernous carotid aneurysms. Working Group Interventional Neuroradiology, France, January 12-16, 1998
167. Kupersmith AAN neuro-ophthalmology course, and paper on giant cell arteritis
168. Turbin R, Kupersmith MJ. Delayed visual loss in patients with giant cell arteritis. Invest Ophthalmol Vis Sci 1998;39:S771
169. Kupersmith ARVO giant cell arteritis quality of life outcome
170. Turbin, Kupersmith Frank Walsh Society chiasm cavernoma
171. Turbin, Kupersmith NANOS visual loss from giant cell arteritis
172. Kupersmith INOS, Dublin, July 1998, Occipital dysfunction from dural AVM
173. Kupersmith MJ. Giant Cell Arteritis 1998. Pennsylvania Ophthalmological Association keynote lecture, June 12, 1998
174. Kupersmith MJ. 2nd International Glaucoma Meeting, Jerusalem, March 1998, Color doppler assessment of orbital blood flow in giant cell arteritis
175. Kupersmith MJ. Working Group in Interventional Neuroradiology, Val D'Sere, January 1998, Aneurysms of the cavernous carotid artery.
176. Speira RF, Mitnick H, Kupersmith MJ, Richmond M, Speira H, Peterson M, Paget SA. A prospective, double-blind, randomized, placebo-controlled trial of methotrexate (combined with corticosteroids) in the treatment of giant cell arteritis (GCA). Arthritis Rheumatism 1998; 41:9
177. Kupersmith MJ. Discussant: Divergence insufficiency. American Academy Ophthalmology. New Orleans, November 9, 1998.

1999

178. Kalish H, Kupersmith MJ. Orbital inflammation in giant cell arteritis. Frank Walsh Society, February 6-7, 1999, Atlanta
179. Kalish H. Kupersmith MJ. Long term outcome of Terson's syndrome. IOVS, ARVO
180. Kupersmith MJ, Woo H. Brainstem cavernoma – natural history. NANOS, March

1999

181. Evans R, Wang JC, Kalish H, Kupersmith MJ. The use of single-photon emission computed tomography in the evaluation traumatic cortical blindness. IOVS, ARVO
 182. Roth R, Kupersmith MJ, Barr D, Turbin R, Bose S. Isolated sixth nerve palsy an uncommon presenting sign of multiple sclerosis: a retrospective study. IOVS, ARVO
 183. Kupersmith MJ. Discussion: Diagnosis and management of divergence weakness in adults. *Ophthalmology* 1999;106:1353-1356
 184. Kupersmith MJ, Woo H. Outcome brainstem cavernoma. European Neuro-ophthalmology Society, Jerusalem, 8/30-9/2
 185. Kalish H, Kupersmith MJ. Cavernous carotid aneurysms - long term natural history. European Neuro-ophthalmology Society, Jerusalem, 8/30-9/2
 186. Kupersmith MJ, Alpert R, Berenstein A, et al. Acute and subacute complications of GDC treatment of intracranial aneurysms. AAN.
- 2000
187. Kupersmith MJ. Pediatric Neuro-ophthalmology. Greater New York Ophthalmology Clinical Lecture Series. Mount Sinai Medical Center, January 5, 2000
 188. Kalish H, Kupersmith MJ. Cavernous sinus dural arteriovenous malformations: patterns of venous drainage. NANOS, Mont Tremblant, March 27, 2000
 189. Kalish H, Kupersmith MJ. The natural history of intraocular hemorrhages associated with non-traumatic subarachnoid hemorrhage. NANOS, March 27, 2000
 190. Alban T, Kupersmith MJ. An unusual case of unilateral loss of vision neuropathy. Frank B. Walsh meeting, March 25, 2000
 191. Alban T, Kupersmith MJ, Zeifer B, Lefton D. Visual outcome and gadolinium MRI in acute optic neuritis. *IOVS* 2000;41: S311
 192. Lakany R, Borohovich S, Kupersmith MJ. Ocular myasthenia gravis management. *IOVS* 2000;41:S709
 193. Kupersmith MJ, Alban T, Zeiffer B, Lefton D, Knopp E. Contrast-enhance MRI in acute optic neuritis. *Neurology* 2000;54 (suppl):A319
 194. Kupersmith MJ, Latkant R, Straga J. Ocular Myasthenia gravis. Myasthenia Gravis Foundation of America Scientific Session. Boston, October 14, 2000
 195. Kupersmith MJ, Kalish H, Niimi Y, Setton A, Huna R, Langer D, Berenstein A. Cavernous carotid aneurysms should not be included in the analysis of intracranial

aneurysms. *Ann Neurol* 2000;48:

2001

196. Kupersmith M, Staga J, Zeiffer B, Krager R. Temporal field loss in ‘unaffected’ eye with acute optic neuritis: a lesion at Wilbrand’s knee. *J Neuro-ophthalmol* 2001;21:143-144
197. Stiebel-Kalish H, Setton A, Berenstein A, Kupersmith MJ. Bilateral orbital congestion as a risk factor for cortical venous drainage in cavernous sinus area dural AVMs. *J Neuro-ophthalmol* 2001;2:138
198. Kupersmith MJ, Lefton D. Acute homonymous quadrantanopia and patent foramen ovale. *Frank Walsh Ann Arbor*, April 21-22, 2001
199. Kupersmith MJ, Straga J, Zeiffer B, Kraker R. Junctional scotoma in acute optic neuritis or inflammation of the ‘Knee’. *Invest Ophthalmol Vis Sci* 2001;42:S326
200. Latkany R, Kupersmith MJ. Ocular myasthenia gravis: effects of edrophonium and prednisone. *Invest Ophthalmol Vis Sci* 2001;42:S844
201. Kupersmith MJ, Huna R. Idiopathic intracranial hypertension in pregnancy: course, management, outcome. *Neurology* 2001;56:A13
202. Kupersmith MJ, Alban T, Zeiffer B, Lefton D. Contrast MRI and visual loss in acute optic neuritis. *EUNOS, Tuebingen*, July 22-26, 2001
203. Kupersmith MJ, Latkany R, Staga J. Ocular myasthenia gravis: steroids, edrophonium dose, thymomas, and generalization. *EUNOS, Tuebingen*, July 22-26, 2001
204. Kupersmith MJ. *Neuro-ophthalmology Symposium. Am Acad Ophthalmol, New Orleans*, October 2001

2002

205. Kupersmith MJ, Fazzone H. Localization of pain associated with optic neuritis. *NANOS, Copper Mountain*, February 11, 2001
206. Fazzone H, Kupersmith MJ. Does Brimonidine help NAION? *NANOS, Copper Mountain*, February 11, 2001
207. Fazzone H, Kupersmith MJ. Brimonidine treatment for NAION. *Invest Ophthalmol Vis Sci* 2002;
208. Kupersmith MJ, Fazzone H. Optic neuritis: correlation of pain and mri. *Invest Ophthalmol Vis Sci* 2002

209. Kupersmith MJ, Galetta S, chairpersons, AAO Symposium on Multiple Sclerosis, Orlando, October 20, 2002

210. Kupersmith MJ, Fazzone H. Ocular motor testing in clinical trials. Clinical Eye Movement Society, New York, October 13, 2002

2003

211. Tamhankar MA, Passero F, Kupersmith MJ, Quiros P, Globe D, Schotland D, Balcer L. Self-reported visual dysfunction in ocular and generalized myasthenia gravis. NANOS 2/10/03, Utah

212. Kupersmith MJ. Ocular myasthenia gravis: edrophonium testing and effects of prednisone on incidence of generalized disease at two years. NANOS 2/11/03, Utah

213. Fazzone H, Kupersmith MJ. Ocular motor duction testing for clinical trials. NANOS 2/12/03, Utah

214. Kupersmith MJ, Fazzone H. Ocular motor duction testing for clinical trials. ARVO 5/5/03, Ft Lauderdale

215. Ponce E, Will D, Rosen R, Gentile R, Kupersmith MJ. Use of scanning laser ophthalmoscope in assessing patients with functional visual loss. ARVO 5/5/03, Ft. Lauderdale

216. Case report: see-saw nystagmus as the presenting sign in an adult male with mri confirmed agenesis of the optic chiasm. ARVO 5/6/03, Ft. Lauderdale

217. Kupersmith M. Intracranial dural arteriovenous shunts (AVMs) in adults- neuro-ophthalmological aspects. *Neuro-ophthalmology* 2003;27:230

218. Kupersmith MJ, Martin V, Shah A, Mitnick HJ, Heller G. Idiopathic hypertrophic pachymeningitis – clinical features and effects of therapy. *Neuro-ophthalmology* 2003;27:232

219. Turbin RE, Thompson CS, Kennerdell JS, Peele-Cockerham K, Kupersmith MJ. Response to letter from Doctor Lee: Optic Nerve Sheath Meningiomas. *Ophthalmology* 2003;110: 1282-3.

2004

220. Kupersmith MJ for ONTT Group. Magnims clinically isolated syndrome workshope. National Hospital at Queens Square London 1/22/04

221. Kupersmith MJ. Magnims clinically isolated syndrome workshope. National Hospital at Queens Square London 1/23/04

222. Tikoo R, Findley J, Kupersmith MJ. Treatment of refractory neurosarcoidosis with 2-CDA. NEJM 2004; 1798-1799
223. Kupersmith MJ for ONTT. 10 year follow up of ONTT study. NANOS, Orlando. March 2004
224. Trastman-Caruso E, Kupersmith MJ. Natural history of meningiomas of the cavernous sinus. NANOS, Orlando, March 2004
225. Kupersmith MJ, Kaminski H. Prospective Survey of NANOS and MGFA Members on Treatment of Ocular Myasthenia Gravis, ARVO, Ft. Lauderdale, May 2004
226. Pro M, Pons M, Zafar S, Kupersmith M. The retinal nerve fiber layer in patients with acute optic neuritis. ARVO, Ft. Lauderdale, May 2004
227. Pons M, Pro M, Samia Zafar S, Kupersmith M. The Retinal Nerve Fiber Layer (RNFL) measured by scanning laser ophthalmoscopy (HRT) in Patients with Optic Neuritis. ARVO, Ft. Lauderdale, May 2004
228. de la Cruz Napoli J, Kupersmith M. Clinical Profile of Bilateral Optic Neuritis, ARVO, Ft. Lauderdale, May 2004
229. Kupersmith MJ, Ying GS. Ocular motor dysfunction in ocular myasthenia gravis: Effects of treatment. AAN, San Francisco, April 2004
230. Friedman D, Cox T, Wall M, Digre K, Kupersmith M, Feldon. Idiopathic intracranial hypertension. AAN, San Francisco, April 2004
231. Brisman J, Song J, Niimi Y, Langer D, Kupersmith M, Fernandez P, Berenstein A. Endovascular treatment of intracranial aneurysms using a new hydrogel-coated self-expandable coil (Hydrocoil): Early experience from a single large volume center. Congress of Neurological Surgeons. San Francisco, October 2004
- 2005
232. Kupersmith M, Pro M, Pons M. Optic Nerve/Nerve Fiber Layer Imaging in Optic Neuritis. NANOS, Copper Mtn., February
233. Kupersmith M, Ying G. Ocular Motor Dysfunction in Ocular Myasthenia Gravis: Effects of Treatment. NANOS, Copper Mtn., February
234. Kupersmith M, Heller G, Cox T. MRI and MRA Evaluation of Third Nerve Palsies and Posterior Communicating Artery Aneurysms, AAN, April

235. Holmes J, Kupersmith M. Quantifying diplopia using a cervical range of motion device. ARVO, Ft Lauderdale, May
236. Ahmad S, Kupersmith M, Brisman J, Niimi Y, Song J, Berenstein A. Cortical blindness following coil embolization of intracranial aneurysm. ARVO, Ft Lauderdale, May
237. Rodriquez N, Kupersmith M. The Long-term Effects of Ethambutol on the Optic Nerve, ARVO, Ft Lauderdale, May
238. Kupersmith M, Heller G, Cox T. MRI/MRA Evaluation of Third Nerve Palsies and Posterior Communicating Artery Aneurysms, EUNOS, Moscow, May
239. Kupersmith M. Early Corticosteroid Therapy Is Indicated for Ocular Myasthenia Gravis: Pro. AAO, Chicago, October 2005
- 2006
240. Heran N, Song J, Kupersmith M, et al. Large Ophthalmic Segment Aneurysms with Anterior Optic Pathway Compression: Assessment of Anatomic and Vision Outcomes after Endosaccular Coiling. AANS, Cerebrovascular Section, February 2006
241. Kupersmith M, Heller G, Cox T. Does the clinical evaluation distinguish third nerve palsies due to ischemia from an unruptured posterior communicating artery aneurysm? ARVO, Ft Lauderdale, April 30
242. Kupersmith M, Gal R, Beck R, Miller N, The Optic Neuritis Study Group. Predictive Value of Baseline and One Month Vision for Permanent Visual Loss after Optic Neuritis- Review of ONTT Database. ACTRIMS, Chicago, October 8, 2006
243. Kupersmith M, Fazzone H. Two gentleman with one cause for visual loss. BINOC. Dublin, Ireland, November 2-4, 2006
- 2007
244. Kupersmith M, Gal R, Beck R, Miller N. Visual Function at Baseline and One Month in Acute Demyelinating Optic Neuritis Predicts Visual Outcome. NANOS, February 12, 2007
245. Huna-Baron R, Kupersmith M. Steroid non-responsive optic neuropathy. Frank Walsh Society, Utah, February 10, 2007
246. Kupersmith MJ, Heran N, Song J, Niimi Y, Namba K, Langer D, Berenstein A. Ophthalmic segment aneurysms with anterior optic pathway compression: anatomic and vision outcomes after endosaccular coiling. ARVO May 2007 ARVO May 6, 2007; session 145
247. Kupersmith MJ. Ocular Myasthenia Gravis Treatment Trial. NY Academy of Medicine meeting, Chicago, May 16, 2007

248. Kupersmith MJ, Heran N, Song J, Niimi Y, Namba K, Langer D, Berenstein A. Parent artery closure or preservation in endovascular treatment of aneurysm visual loss. EUNOS 2007, May 2007, Istanbul, Turkey

249. Kupersmith, MJ. Canadian Ophthalmological Society, Montreal, June 2007

250. Kupersmith MJ, ONTT Study Group. 15-year Neurologic outcome Optic Neuritis Treatment Trial patients. Charcot Society, ACTRIM, Prague, October 2007

251. Wang S, Yu J, Knisely J, Kupersmith M, Lesser R. Response to radiotherapy of optic nerve sheath meningiomas. AAO, New Orleans, November 2007

2008

252. Kupersmith M, Kardon R, Mandel G, Anderson S. Swelling of the Peripapillary RNFL in Optic Neuritis – Presentation, Relation to Baseline MRI and Vision, Resolution and Subsequent Thinning. AAN 2008. *Neurol* 70; 2008 (Suppl 1); A128

253. Kupersmith M, Mandel G, Anderson S, Kardon R. Acute Optic Imaging of the Peripapillary RNFL in Optic Neuritis - Alterations in Birefringence and Retardance Properties. *Invest Ophthalmol Vis Sci* 2008;49: E-Abstract 5389

254. Kupersmith M, Mandel G, Anderson S, Kardon R. Retinal Nerve Fiber Layer Thinning After Acute Optic Neuritis: Relationship to Baseline and 1 Month Vision and RNFL Changes. ECTRIMS Sept 2008 (accepted but withdrawn due to administrative issues)

255. Kupersmith M, Mandel G, Anderson S, Kardon R. Prospective Evaluation of the Retinal Nerve Fiber Layer in Acute Optic Neuritis Shows Thickening Followed by Thinning. INOS June 2008

256. Kupersmith, M. Rationalizing GCA Treatment and Preventing Vision Loss. 4th International Conference on Giant Cell Arteritis and Polymyalgia Rheumatica, NY, NY, July 31 – August 1, 2008.

2009

257. Kupersmith M, Mandel G, Anderson S, Kardon R. Prospective Analysis Of The Retinal Nerve Fiber Layer In Acute Optic Neuritis And At 1, 3, And 6 Months. Incline Village NV, NANOS February 2009

258. Kupersmith M. Ocular Myasthenia Gravis: Treatment Successes and Failures in Patients with Long Term Follow Up. Seattle, AAN 2009; *Neurology* 72; 2009 (suppl 3)A440

259. Kupersmith M, Mandel G, Anderson S, Kardon R. Retinal nerve fiber layer thinning after acute optic neuritis: importance of 1 month findings. S0.005; *Neurology* 72; 2009 (suppl 3); A98

260. Gupta A, Kupersmith M, Meltzer D. Magnetic Resonance Imaging Distinguishes Optic Perineuritis from Typical Optic Neuritis. Ft. Lauderdale, ARVO May 2009
261. Schulman J, Mandel G, Kupersmith M. Differentiating Extra-cellular Edema from Axonal Thickening in Papilledema Using OCT and SLP. Invest Ophthalmol Vis Sci 2009;50: E-Abstract 932
262. Kupersmith M, Zhou Q, Mandel G, Atkinson V, Anderson S, Kardon R. Retinal nerve fiber layer birefringence: Acute reduction and recovery in optic neuritis. Invest Ophthalmol Vis Sci 2009;50: E-Abstract 5664
263. Anderson S, Kupersmith M, Mandel G, Kardon R. **One Month Findings Predict Retinal Nerve Fiber Layer (RNFL) Loss at 6 Months After Acute Optic Neuritis;**. Invest Ophthalmol Vis Sci 2009;50: E-Abstract 926
264. Kupersmith, MJ. Optic Neuritis as an In Vivo Model to Test Neuroprotective Agents. ISOPT, Rome Dec 4, 2009
265. Horne M, Kupersmith MJ. Ocular Coherence Tomography and Scanning Laser Polarimetry Differentiation of Swollen Optic Nerves. ISOPT. Rome, Dec 6, 2009
- 2010
266. Kupersmith M, P. Sibony, G. Mandel, M. Durbin, R.H. Kardon. Is Papilledema the Reverse of Glaucoma? OCT Demonstration of Biomechanical Alterations of the Optic Nerve. ARVO
267. M.J. Kupersmith, P. Sibony, G. Mandel, M. Durbin, R.H. Kardon .Poster Session 126. Retinal and Optic Nerve Imaging 646/A554 -ARVO
268. Mandel G, et al. IOVS 2010;51:ARVO-EAbstract 555. - Spectral Domain OCT Parameters to Measure Papilledema Due to Intracranial Hypertension
- 2011
269. Patrick Sibony, MD, Mark Kupersmith Geometric Morphometrics defines peripapillary RPE shape deformations in papilledema. ARVO, May 2011, Ft Lauderdale
270. Wang J-K, Kardon R, Antony B, Kupersmith M, Garvin M. Comparison of an Automated Method for Volumetric Quantification of Papilledema with the Frisén Scale. Invest Ophthalmol Vis Sci 2011;52: E-Abstract 2986
271. Kupersmith M, Mandel G, Horne H, Durbin M, Kardon R. Optical Imaging Differentiation of RNFL Changes Due to Intracranial Hypertension, Ischemia and Inflammation. Invest Ophthalmol Vis Sci 2011;52: E-Abstract 5309

272. Kupersmith M, Sibony P, Mandel G, Durbin M, Kardon R, MD, Optical coherence tomography of the swollen optic nerve head: deformation of the peripapillary RPE layer in papilledema. North American Neuro-Ophthalmology Society, February , 2011, Vancouver
- 2012
273. Sibony P, Kupersmith M. Geometric Morphometrics of the Peripapillary SD-OCT: shape analysis of the RPE layer in papilledema and ischemic optic neuropathy. North American Neuro-Ophthalmology Society, February 11-16, 2012, San Antonio
274. Sibony P, Honkanen R, Kupersmith M, Strachovsky M. Geometric Morphometric Analysis of the Peripapillary RPE- layer in Optic Nerve Sheath Meningiomas. ARVO, May 2012, Ft Lauderdale
275. Sibony et al. *Inv Ophthalmol Vis Sci* 2012;53 :ARVO E-abstract 3930
276. Kupersmith M, Kardon R, Anderson S, Durbin M. Structure/Function Outcomes and Correlations with Scanning Laser Polarimetry of Acute NAION. ARVO, May 2012, Ft Lauderdale
277. Kupersmith et al. *Inv Ophthalmol Vis Sci* 2012;53 :ARVO E-abstract 1307
278. Bruce B, Kupersmith M. Safety of Prednisone for Ocular Myasthenia Gravis. North American Neuro-Ophthalmology Society, February 11-16, 2012, San Antonio
279. Kupersmith M, Kardon R, Durbin M. Distinguishing Retinal Nerve Fiber Layer Injury by Optical Imaging in Acute Optic Nerve Head Swelling. North American Neuro-Ophthalmology Society, February 11-16, 2012, San Antonio
280. Wall M, NORDIC IIHTT Study Group. Idiopathic Intracranial Hypertension Treatment Trial (IIHTT) Update. North American Neuro-Ophthalmology Society, February 11-16, 2012, San Antonio
281. Wang J, Kardon R, Kupersmith M, Garvin M. Automated SD-OCT volumetric estimation of severe papilledema: overcoming truncated scans. ARVO, May 2012, Ft Lauderdale
282. Wang et al. *Inv Ophthalmol Vis Sci* 2012;53 :ARVO E-abstract 3922
283. Kupersmith M. Lessons Learned from Mistakes by “Experts” in Treating Neurovascular Disorders. North American Neuro-Ophthalmology Society, February 11-16, 2012, San Antonio
284. Kupersmith M, Kardon R, Horne M, Shulman J, Durbin M. Retinal Nerve Fiber Layer Alteration Differences between OCT and SLP with Optic Nerve Head Swelling. AAN April 2012, New Orleans

285. Kupersmith M, Sergott R, Hurtukova D, Calabresi P, Cutter G. The effects of glatiramer acetate on the retinal nerve fibre layer in patients with a first episode of acute optic neuritis. ECTRIMS, Lyon, France, October 12, 2012 (Abstract 1144)

2013

286. Kupersmith M, Anderson S, Durbin M, Kardon R. Acute Changes in Retinal Birefringence at Onset of NAION Reveals Axonal Injury Corresponding to Permanent Regional Visual Field Loss NANOS February 2013, Snowbird, UT

287. Kupersmith MJ Loss of Peripapillary Birefringence at Presentation of Acute NAION Correlates with Baseline and Permanent Regional Visual Field Deficits. AAN March 2013, San Diego, CA

288. Kupersmith, M; Garvin M; Wang J-K; Kardon, R. Early Retinal Ganglion Cell Layer Thinning Due to Acute NAION and Optic Neuritis.

289. Kupersmith et al. *Inv Ophthalmol Vis Sci* 2013;54:ARVO E-abstract 3233

2014

290. Lee M, Bruce B, Whittaker T, Kupersmith. Demographics of Ocular Myasthenia Gravis. NANOS

291. OCT Sub-Study Committee for the NORDIC IIHTT Study Group. Baseline Optical Coherence Tomography (OCT) Measurements in the Idiopathic Intracranial Hypertension Treatment Trial: Correlations and Relationship to Clinical Features. AAN

292. Kupersmith M, Wang J, Garvin M, Kardon. Retinal Ganglion Cell Layer Thinning within One Month of Presentation for Non-arteritic Anterior Ischemic Optic Neuropathy and Optic Neuritis, AAN

293. Friedman D for IIHTT Study Group. Headache at baseline in IIHTT study subjects. AAN.

294. Sibony P, Honkanen R, Kupersmith Rohlff FJ. Peripapillary RPE-layer shape changes in Intracranial Hypertension before and after treatment. ARVO and NANOS

295. Wang J-K, et al. *IOVS* 2014; 515: ARVO E-Abstract 5780-B0116

296. OCT Sub-Study Committee for the NORDIC IIHTT Study Group. *IOVS* 2014:ARVO E-Abstract ...

296. Kupersmith MJ, Wang J, Garvin M, Kardon R. Retinal ganglion cell layer thinning and vision outcome in optic neuritis over six months. Actrims-Ectrims, Boston, 9/12/14

2015

297. Jui-Kai Wang, Patrick A. Sibony, Randy H. Kardon M.D., Mark J. Kupersmith, Mona K. Garvin, "Semi-automated 2D Bruch's membrane shape analysis in papilledema using spectral-domain optical coherence tomography," *Proc. SPIE9417*, Medical Imaging 2015: Biomedical Applications in Molecular, Structural, and Functional Imaging.

Prior Grants:

1. Optic Neuritis Treatment Trial, NEI funded Grant. NYU Site, PI Mark J. Kupersmith, 3/1/88 - 2/29/92. Initial Budget \$185,807 - determined by subject enrollment.
2. Grant funded from Fight for Sight: Dopaminergic influences on human visual function. Principal Investigator Mark J. Kupersmith, M.D., funding 9/1/88 - 8/31/89, \$9,000.
3. Visual Science Center - Principal Investigator Mark J. Kupersmith, M.D., R.L. Kohn's Foundation, 1988-present, \$250,000.
4. Longitudinal Optic Neuritis Study, NEI Funded Grant. NYU Site PI, Mark J. Kupersmith. 3/1/92-2/28/97, \$30,000.
5. Extended Optic Neuritis Study, NEI Funded – Roy Beck, PI; Mark J. Kupersmith sub-investigator; 2001-2002.
6. Visual Loss from Pituitary Adenoma in Pregnancy. Sandoz Pharmaceutical funded. Principal Investigator Mark J. Kupersmith, M.D., renewal previously \$12,500 and \$5,000 1992-1993.
7. Methotrexate treatment trial giant cell arteritis. Arthritis Foundation. Principal Investigator - Stephen Paget, M.D.; visual studies PI - Mark J. Kupersmith; funding from AARP Andrus Foundation (PI:MJK; \$75,000).
8. Randomized, double blind, placebo controlled study of AVONEX (interferon beta-1a) in the treatment of subjects at high risk for development of multiple sclerosis following the first onset of an isolated demyelinating event. NYU Site PI Mark J. Kupersmith. Biogen Corporation sponsored. 6/96-7/01, \$218,000.
9. Antegren treatment of MS exacerbation. Joseph Herbert, M.D. PI; Mark J. Kupersmith, M.D. investigator, 2002
10. Neuroprotection in Ischemic Optic Neuropathy. Allergan. Mark J. Kupersmith, sub-investigator, 2001-2003. Study stopped for lack of enrollment
11. Extended Optic Neuritis Study, NEI Funded – Roy Beck, PI; Mark J. Kupersmith sub-investigator; 2001-2006

12. Prednisone Ocular Myasthenia Gravis Trial Planning Grant. (P)I – NINDS, R34 NS46283-01A1, MJ Kupersmith PI, \$203,608; 08/17/04-06/01/06
13. Optic Neuritis as a Model for Acute Neuronal Injury using Ocular Imaging. Pearle Vision Foundation. MJ Kupersmith PI, \$14,000, 2007-2008
14. Oral Megadose Corticosteroid Therapy of Acute Exacerbations in MS (OMEGA). F Lublin PI, MJ Kupersmith co-PI, \$790,000, National MS Society, 2001-2008
15. Neuro-Ophthalmology Research Disease Investigator Consortium (NORDIC); M J Kupersmith Chair; U10 NEI. \$ 9,835,688 February 1, 2009- January 31, 2015

Patents:

Method and apparatus for visual evoked responses: Patent #4,676,611, Jeremiah Nelson and Mark Kupersmith.

Consultant Studies:

Mirapex Ocular Safety Study – 200 Subject, 20 center study. M J Kupersmith (co-PI and Consultant, study design, outcome analysis); Boehringer Ingelheim. \$6,000,000 total cost, 2005-present